| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Redhill Biopharma Ltd.$0.7
-0.01 (-1.65%)
C 49Pipeline Score Fair Value Pharma · Clinical
Market Cap
5.09 M
EPS
-
P/E Ratio
-
Value Trade
167.49 K
-2.02 %
Week
18.96 %
1 Month
-2.02 %
3 Month
-4.87 %
6 Month
-99.99 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
38.21 K
52 Week Range
0.71 - 3.31
% held by Insiders
11.09 %
% held by Institutions
2.76 %
Enterprise Value
2.19 M
Total Shares
5.19 M
Short %
0.26 %
Float Shares
4.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Redhill Biopharma Ltd.
1718Total events
4Upcoming
453Tier-1 (high impact)
2012 – 2042Coverage
Upcoming catalysts 4
TBD
T1Designation Withdrawn
Expected transfer of RHB-104's FDA pediatric orphan drug designation to RHB-204
Event history 1714
Jun 22, 2026
▼Equity OfferingCorporate
Closing of private placement raising $6 million upfront with potential additional $13.4 million from warrant exercise
Jun 9, 2026
▲Rare Pediatric DiseaseopaganibDesignation
FDA granted rare pediatric disease designation to opaganib for neuroblastoma
neuroblastomasource ↗
Jun 3, 2026
◆Partnership / LicenseopaganibCorporate
Actively discussing potential collaborations for opaganib in EVD, including WHO SOLIDARITY CORE platform
Ebola virus diseasesource ↗
Jun 2, 2026
◆Partnership / LicenseopaganibCorporate
Active discussions for potential collaborations including WHO SOLIDARITY CORE platform
Ebola virus diseasesource ↗
Apr 30, 2026
▲Preclinical PoCRHB-204Preclinical
RHB-204 demonstrates comparable MAP killing efficacy to RHB-104 in in vitro assays
Crohn's diseasesource ↗
Apr 27, 2026
Apr 22, 2026
▲Poster PresentationopaganibPresentation
Poster presentation at AACR 2026: Opaganib potentiates STING activation in TNBC in vitro
triple-negative breast cancersource ↗
Feb 25, 2026
▲Product LaunchTALICIA®ApprovedPost-Market
Full sales and operational launch of Talicia under joint commercialization agreement with Cumberland
H. pylori infectionsource ↗
Feb 2026
▲Product LaunchTALICIA®ApprovedPost-Market
Full sales and operational launch of Talicia by THI
H. pylori infectionsource ↗
2026
▲Poster PresentationopaganibPresentation
Preclinical data presented at AACR 2026 showing positive effects in neuroblastoma and TNBC models
neuroblastoma and triple-negative breast cancersource ↗
2026
◆Trial InitiationRHB-102Trial
Phase 2 Proof-of-Concept study planned to commence as early as possible in 2026
GLP-1/GIP receptor agonist therapy-associated GI side effectssource ↗
Drug Pipeline Intelligence
C49
Pipeline Score $14M
Pipeline ValueFair Value
Valuation Signal8
Drugs Scored2.7x
rNPV / MCap Top 73%
Micro Cap (rank 247 of 911)
Percentile RankRedhill Biopharma Ltd. carries a moderate pipeline score (49/100), with $5.4B risk-adjusted pipeline value, led by RHB-104 in Crohn's Disease (Phase 3), across $73B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RHB-104 Small molecule | Crohn's Disease | Phase 3 | NCT01951326 | 58% | $1.7B | COMPLETED | 331 | - | - | Aug 1, 2019 | - | Dec 8, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RHB-104 | Crohn's disease | Phase 3 | 2026-04-30 | 64% more effective than SoC alone, p = 0.0048 | RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease Read More | |
RHB-104 | Crohn's disease | Phase 3 | 2026-04-30 | 64% more effective than SoC alone, p = 0.0048 | RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease Read More | |
RHB-104 | Crohn's disease | Phase 3 | 2026-04-30 | 64% more effective than SoC alone, p = 0.0048 | RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RDHL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RDHL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RDHL▲ +10.2%on this news
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma has successfully closed a private placement, raising $6 million upfront with the potential for an additional $13.4 million through warrants. The funds are aimed at enhancing the company's liquidity and supporting potential acquisitions of revenue-generating pharmaceutical assets. However, no definitive acquisition agreement is in place, and the transaction is subject to various conditions.
Read more →RDHLRedHill Biopharma Announces Up To $19.4 Million Private Placement
RedHill Biopharma has announced a definitive agreement for a private placement of American Depositary Shares (ADSs) expected to raise up to $19.4 million. The initial $6 million will be supplemented by potential proceeds from warrants. The funds are intended for strategic acquisitions and general corporate purposes, but there are no guarantees regarding the exercise of warrants or completion of acquisitions.
Read more →RDHL▼ -21.6%on this news
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of ...
RedHill Biopharma announced that the FDA has granted its drug opaganib a rare pediatric disease designation for treating neuroblastoma, a cancer primarily affecting infants and young children. This designation complements its existing orphan drug status, offering potential advantages like accelerated review processes and marketing exclusivity if approved. Newly presented preclinical data indicate opaganib's positive effects as a potential add-on therapy in neuroblastoma treatment. The global market for neuroblastoma is expected to reach approximately $3.5 billion by 2032.
Read more →RDHLRedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RedHill Biopharma has initiated enforcement proceedings in Korea following a New York Supreme Court judgment awarding approximately $10.9 million against Kukbo Co. Ltd. This includes a principal amount and legal fees. The company awaits Kukbo's response while recognizing that recovery timing and amounts remain uncertain.
Read more →RDHLRedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak
RedHill Biopharma is actively pursuing collaborations to advance the clinical application of opaganib to combat Ebola Virus Disease, particularly amid an outbreak of the Bundibugyo ebolavirus subtype. Recent data suggests that opaganib could significantly reduce mortality rates and improve viral clearance times based on its performance in severe COVID-19 treatment. Although promising, opaganib remains an investigational product that has yet to receive regulatory approval, and its inclusion in key clinical trial platforms like WHO's SOLIDARITY CORE is not assured.
Read more →RDHLRedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
RedHill Biopharma is exploring collaborations to advance opaganib for treating the current Ebola outbreak caused by the Bundibugyo ebolavirus subtype. The company is discussing its investigational oral drug's potential with the WHO's SOLIDARITY CORE clinical trial platform. Opaganib has shown promising antiviral properties and a favorable safety profile, making it a candidate for addressing this public health threat.
Read more →RDHLRedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RedHill Biopharma's RHB-204 has demonstrated comparable efficacy in killing Mycobacterium avium subspecies paratuberculosis (MAP) to RHB-104 in recent studies. This next-generation formulation aims to enhance tolerability and safety for Crohn's disease patients. The upcoming Phase 2 study is set to be the first controlled clinical trial in a MAP-positive patient population, potentially revolutionizing treatment approaches.
Read more →RDHLRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
RedHill Biopharma reported its 2025 financial results, highlighting strategic transactions including the establishment of Talicia Holdings Inc. and a partnership with Cumberland Pharmaceuticals. Despite facing operating losses of $7.9 million, the company noted a significant turnaround in net income from discontinued operations resulting from a gain on the loss of control over Talicia. The R&D pipeline is progressing, especially with RHB-204 for Crohn's disease and opaganib in oncology. Overall, RedHill indicated a sound position for future growth and market expansion.
Read more →RDHL▲ +5.8%on this news· ran to +29% by day 1shared move
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show...
New preclinical data presented at the 2026 AACR Annual Meeting highlights the potential of opaganib, a drug developed by RedHill Biopharma, as an add-on therapy for neuroblastoma and triple-negative breast cancer. Studies indicate that opaganib enhances the efficacy of existing chemotherapy treatments by destabilizing the oncogenic driver n-Myc in neuroblastoma and augmenting anti-tumor immunity in triple-negative breast cancer. The findings from this research may support further clinical development of opaganib in oncology indications, especially considering its FDA Orphan Drug designation for neuroblastoma.
Read more →RDHLJoint U.S. Commercialization of RedHill's Talicia® Commences
RedHill Biopharma and Cumberland Pharmaceuticals have commenced the full sales and operational launch of Talicia, an FDA-approved treatment for H. pylori infection. This joint commercialization aims to enhance market penetration and patient access to Talicia, which is recognized as the leading therapy for H. pylori. The collaboration is expected to leverage combined expertise for improved prescription growth and operational efficiencies.
Read more →RDHL▲ +35.9%on this news
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RedHill Biopharma announced progress in the development of RHB-102, a once-daily oral ondansetron formulation aimed at treating gastrointestinal side effects associated with GLP-1 receptor agonist therapies. The drug has shown positive results in Phase 2 and Phase 3 studies for various indications, including IBS-D and gastroenteritis. RedHill plans to pursue FDA approval through the accelerated 505(b)(2) pathway.
Read more →RDHLRedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
RedHill Biopharma announced positive results from a study showing that opaganib, a sphingosine kinase 2 inhibitor, combined with venetoclax, reduces chronic lymphocytic leukemia (CLL) cell counts by 50%. This finding highlights opaganib's potential as an effective add-on therapy for patients resistant to venetoclax. The results are based on in vivo studies and support ongoing clinical evaluations.
Read more →RDHLRedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
RedHill Biopharma announced that it has regained compliance with Nasdaq's stockholders' equity requirement as of November 26, 2025. This achievement is part of the company's strategic initiatives, including a partnership with Cumberland Pharmaceuticals for the promotion of Talicia. The company continues to focus on operational efficiency and development of its drug pipeline.
Read more →RDHL▼ -13.6%on this news
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
RedHill Biopharma announced that the New York Supreme Court's judgment in its favor against Kukbo Co. Ltd is now final, allowing for enforcement. The court awarded RedHill over $10.5 million, including approximately $8.6 million in the main judgment and $1.9 million for legal fees. Additionally, RedHill has secured a Korean court attachment to prevent Kukbo from disposing of assets.
Read more →RDHLRedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
RedHill Biopharma has secured a $4 million strategic investment from Cumberland Pharmaceuticals, acquiring a 30% stake in RedHill's Talicia business. This partnership aims to enhance Talicia's market presence and sales through shared operational responsibilities and marketing support. Talicia is recognized as a leading therapy for H. pylori infections and is protected by patents until 2042.
Read more →RDHLRedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
RedHill Biopharma has signed a licensing agreement worth $1.8 million for its drug Talicia in the Middle East. The deal includes guaranteed payments and potential milestone payments, alongside tiered royalties based on net sales. Talicia is recognized for its effectiveness against H. pylori, a major risk factor for gastric cancer, and is the only FDA-approved therapy of its kind. This agreement aims to enhance patient access to Talicia in a region with a high prevalence of H. pylori infections.
Read more →RDHL▲ +27.2%on this news
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
RedHill Biopharma has successfully upheld a $10 million summary judgment against Kukbo Co. Ltd. in the New York Supreme Court. The court dismissed Kukbo's defense, confirming that RedHill met its obligations despite Kukbo's breach of contract. This ruling includes an original award of $8.25 million and additional legal costs. Kukbo retains the right to appeal the decision.
Read more →RDHL▲ +16.5%on this news
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
RedHill Biopharma reported its financial results for the first half of 2025, highlighting significant operational improvements and revenue growth. The company has received FDA approval for its innovative Crohn's disease program and is making strides in commercializing Talicia. Despite a net loss increase, the overall financial performance shows positive momentum.
Read more →RDHL▲ +16.5%on this newsshared move
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on m
RedHill Biopharma announced its financial results for the first half of 2025, highlighting a strategic overhaul that has led to considerable progress. The company reported an increase in net revenues, particularly from its product Talicia, which maintained a strong market position. Key developments include the initiation of a Phase 2 study for opaganib and FDA approval for a new Crohn's disease program. Despite a net loss of $4.1 million for the period, the company is taking steps to enhance operational efficiency and drive growth through geographic expansion and licensing agreements.
Read more →RDHLRedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
RedHill Biopharma has been awarded approximately $1.82 million in legal costs by the New York Supreme Court, in addition to a prior summary judgment of $8.25 million against Kukbo Co. Ltd. This brings the total financial award to about $10.07 million. RedHill also secured a court-ordered asset seizure against Kukbo to prevent asset disposal while the appeal process is ongoing.
Read more →RDHL▲ +8.3%on this newsshared move
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
RedHill Biopharma has announced the receipt of $1.1 million in licensing payments for Talicia, following its first ex-U.S. commercial launch. Talicia is the first FDA-approved rifabutin-based treatment for Helicobacter pylori, which poses significant health risks globally. The company aims to expand Talicia's market presence and is exploring additional licensing opportunities.
Read more →RDHLRedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
RedHill Biopharma has received positive feedback from the FDA regarding its RHB-204 Crohn's disease program. This feedback supports the planned Phase 2 study, which aims to test RHB-204 on MAP-positive patients. The company is pursuing non-dilutive funding and expects to benefit from various regulatory designations, enhancing the drug's market potential.
Read more →RDHLRedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
RedHill Biopharma has initiated recruitment for a Phase 2 study evaluating the combination of opaganib and darolutamide in patients with advanced prostate cancer. The study, sponsored by ANZUP and supported by Bayer, aims to utilize a lipid biomarker test to identify patients who may benefit most from this treatment. The trial will take place across multiple sites in Australia and New Zealand, focusing on improving patient outcomes in a challenging cancer type.
Read more →RDHL▼ -5.5%on this news
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill
RedHill Biopharma has achieved a significant victory in its legal disputes with Kukbo Co. Ltd. The Incheon District Court in South Korea has granted an asset freeze on Kukbo's assets, preventing any disposal before the enforcement of a New York Supreme Court judgment amounting to approximately $8.25 million. This judgment includes accrued interest pending Kukbo's compliance with previous licensing agreements. Kukbo now has the right to appeal this judgment by June 2025, which introduces an element of uncertainty into the proceedings.
Read more →RDHLRedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
RedHill Biopharma has announced its support for an independent medical education grant that includes a new two-part Continuing Medical Education (CME) program on H. pylori, developed by Medscape. The first part will be livestreamed during a major gastroenterology meeting on May 6, and aims to enhance clinical knowledge among healthcare professionals regarding H. pylori management. This initiative reflects RedHill's commitment to addressing antibiotic resistance and improving treatment outcomes for patients affected by H. pylori infection.
Read more →RDHL▼ -10%on this news
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
RedHill Biopharma has announced the allowance of a significant Chinese patent application for its investigational COVID-19 treatment, RHB-107. This achievement grants composition-of-matter protection, solidifying market exclusivity and positioning RedHill strongly within the competitive $3 billion COVID-19 therapeutic market. Initial clinical trials of RHB-107 demonstrated encouraging results, including a complete reduction in hospitalization rates among treated patients. The company plans to further its development efforts supported by non-dilutive funding from U.S. government sources.
Read more →RDHL▲ +9.2%on this news
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders
RedHill Biopharma has received a Notification Letter from Nasdaq regarding non-compliance with a listing requirement due to a reported stockholders' deficit. Although this notification does not have an immediate impact on its listing status, the company must submit a compliance plan within 45 days. RedHill is actively looking into strategies to regain compliance and maintain its listing, but future success is uncertain.
Read more →RDHLRedHill Biopharma
RedHill Biopharma has published promising results for Opaganib, indicating its capability to induce weight loss and improve metabolic markers comparable to semaglutide in preclinical models. The therapy works through a unique mechanism by targeting sphingosine kinase-2, offering a differentiated oral treatment option that may reduce common side effects associated with GLP-1 inhibitors. The global obesity-diabetes drug market is projected to reach $100 billion by 2034, and Opaganib's favorable safety data could facilitate a quicker path to FDA approval. The drug's potential extends to various other medical conditions, including cancer and viral diseases.
Read more →RDHLRedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
RedHill Biopharma has announced its full-year 2024 financial results, highlighting a 23% increase in net revenues to $8 million. The company achieved significant advancements, including a $60 million licensing deal for RHB-102 and a successful Phase 2 study of opaganib in prostate cancer. However, RedHill reported a net loss of $8.3 million for the year and a decrease in total assets. Ongoing cost-cutting measures have reduced cash burn by 74% year-over-year, contributing to an overall positive outlook for the company's developmental pipeline.
Read more →RDHLRedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
RedHill Biopharma plans to submit a UK Marketing Authorisation Application (MAA) for Talicia, an FDA-approved treatment for H. pylori infection, using a fast-track approval process. The application aims for UK approval referencing the FDA's previous endorsement, with potential authorisation expected by the end of 2025. Talicia, recognized as the first-line treatment for H. pylori, has seen success in the U.S. and UAE, with plans to expand its availability into the UK and potentially other markets. The significance of this submission stems from the widespread prevalence of H. pylori infections and their correlation with serious health risks such as gastric cancer.
Read more →RDHLRedHill Biopharma Advances its Groundbreaking Late-Stage Crohn
RedHill Biopharma has announced an innovative Phase 2 study for RHB-204, a next-generation therapy targeting Mycobacterium avium subspecies paratuberculosis-positive Crohn's disease patients. This groundbreaking trial, set to include only MAP-positive patients, aims to correlate mucosal healing with infection eradication. RHB-204 builds on the success of RHB-104, which previously demonstrated notable efficacy in a Phase 3 trial. The study is designed to be efficient and cost-effective, with results expected in an expedited timeframe.
Read more →RDHL▼ -6.5%on this news· ran to -18% by day 3
RedHill Presents Business Update at the Sachs
RedHill Biopharma recently presented a significant business update at the European Life Sciences CEO Forum, highlighting multiple advances. Among these, the out-licensing of RHB-102 to Hyloris was emphasized, along with the initiation of a Phase 2 clinical study of opaganib for advanced prostate cancer. Additionally, the company reported commercial progress with its drug Talicia, which has now surpassed 100,000 prescriptions, secured more market access through Humana’s Part D Plan, and launched in the UAE. The outlook for Talicia appears promising with ongoing discussions aimed at reducing production costs and expanding market presence.
Read more →RDHL▼ -11.8%on this news· ran to -31% by day 3shared move
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
RedHill Biopharma has entered into a licensing agreement with Hyloris Pharmaceuticals for RHB-102, covering commercialization outside North America. The deal includes an upfront payment and up to $60 million in milestone payments, alongside royalties on sales. RHB-102, a new oral formulation for treating nausea, is on a promising pathway toward UK regulatory approval following favorable advice from MHRA. The agreement aims to leverage a significant market opportunity in the antiemetics segment, which is projected to grow substantially in the coming years.
Read more →RDHLRedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
RedHill Biopharma has announced the initiation of a Phase 2 clinical study aimed at evaluating the combination of opaganib and darolutamide in men diagnosed with metastatic castrate-resistant prostate cancer (mCRPC). The study, financially supported by Bayer and the Ramsay Hospital Research Foundation, involves 80 patients and aims to test whether opaganib can enhance the effectiveness of darolutamide. Key endpoints include improved radiographic progression-free survival, especially for patients identified as having a poor prognosis due to standard treatment resistance. Professor Lisa Horvath leads the study, emphasizing a novel pathway targeting treatment-resistant cancer cells.
Read more →RDHL▲ +12.3%on this news
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare...
RedHill Biopharma announced that Talicia, a therapy for H. pylori infection, is now covered under Humana's Part D Plan, increasing access for over eight million Medicare beneficiaries. The updated clinical guidelines from the American College of Gastroenterology also name Talicia as a first-line treatment. Additionally, recent research supports a more patient-friendly three-times daily dosing regimen, demonstrating its pharmacokinetic equivalence to the previous routine. This development aims to improve adherence and optimize treatment outcomes for patients experiencing H. pylori infections.
Read more →RDHL▲ +8.8%on this news
Radioprotective Activity of RedHill
RedHill Biopharma reported positive results from new studies of opaganib as a treatment for gastrointestinal acute radiation syndrome (GI-ARS). This research is part of the U.S. government's Radiation and Nuclear Countermeasures Program, aiming to advance opaganib toward FDA approval under the Animal Rule pathway. Discussions with the NIH's NIAID are underway to determine the next development phases. Opaganib is noted for its stability, broad application potential in various conditions, and suitability as a medical countermeasure for emergencies.
Read more →RDHLRedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
RedHill Biopharma has been awarded a judgment of approximately $8 million plus costs by the New York Supreme Court in its case against Kukbo Co. Ltd. The court's decision dismissed all counterclaims from Kukbo, reinforcing RedHill's commitment to the agreements made. RedHill is set to pursue the collection of the judgment and its attorneys' fees, although there remains the possibility of an appeal by Kukbo, which could prolong the legal process. The ruling represents a significant victory for RedHill in the ongoing legal dispute.
Read more →RDHLRedHill Selected to Present Opaganib at Conference Organized by U.S. Government
RedHill Biopharma has been selected to present its investigational drug opaganib at the U.S. government's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's Industry Day. This event is scheduled for October 29-30, 2024, and aims to highlight therapeutics capable of addressing threats from viruses, bacteria, and toxins. Opaganib, a host-directed, orally administered small molecule with various applications, has garnered attention due to its potential in pandemic preparedness and has already participated in multiple ongoing collaborations with U.S. government agencies.
Read more →RDHLRedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
RedHill Biopharma has announced a collaboration with Duke University to advance the development of opaganib as a treatment for phosgene inhalation injury, which poses severe health risks. The partnership will focus on multiple in vivo studies to assess the drug’s effectiveness, potentially leading to government-sponsored development under FDA guidelines. Opaganib aims to address an urgent need for countermeasures against phosgene, a highly toxic chemical linked to potential bioterrorism threats. The drug’s established safety and efficacy make it a candidate for rapid advancement through regulatory pathways.
Read more →RDHLRedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
RedHill Biopharma has received funding from the U.S. government's BARDA to advance opaganib, a novel treatment for Ebola virus disease. This funding supports ongoing development efforts utilizing the FDA's Animal Rule pathway, which is crucial for drugs targeting diseases with ethical challenges for human testing. Recent studies have shown that opaganib significantly increases survival in animal models, marking it as a potential game-changer in global health preparedness. Its unique capabilities as a host-directed therapeutic could mitigate the impacts of future Ebola outbreaks and other viral infections.
Read more →RDHL▼ -5%on this news
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
RedHill Biopharma has successfully renewed its contract with Medi-Cal, ensuring that Talicia remains a first-line treatment for H. pylori infection with $0 copay for 15 million Californians. This agreement emphasizes the commitment to enhancing patient access and aligns with recent clinical guidelines by the American College of Gastroenterology. Talicia's unique formulation, which simplifies the treatment process, further underlines its importance in combating H. pylori infections, a significant health concern.
Read more →RDHLRedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
RedHill Biopharma announced a new U.S. patent for opaganib, a treatment for COVID-19, valid until 2041. This patent is based on promising clinical data showing improved patient outcomes for those with coronavirus pneumonia who received opaganib. The drug demonstrated noteworthy results in a Phase 2/3 study, including reductions in mortality and the need for supplemental oxygen. RedHill's collaborations with U.S. government agencies for pandemic preparedness further bolster opaganib's potential impact.
Read more →RDHL▲ +9.8%on this news· ran to +30% by day 1
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines First new American College of Gastroenterology (ACG) Clinical Guideline[1] for H. pylori infection since Talicia's approval lists Talicia as an...
RedHill Biopharma's Talicia has been listed as a first-line option for H. pylori infection in the new American College of Gastroenterology Clinical Guideline. This marks the first update since Talicia's approval and endorses its all-in-one formulation, which simplifies treatment without the need for prior resistance testing. Talicia's low resistance rates bolster its position as an effective therapy for this widespread infection. Moreover, its inclusion in clinical guidelines reflects a significant shift in treatment practices for H. pylori-related conditions.
Read more →RDHLRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
RedHill Biopharma has confirmed its compliance with the Nasdaq minimum bid price requirement, allowing it to continue listing on The Nasdaq Capital Market. The company achieved this by maintaining a closing bid price of $1.00 per share for at least 10 consecutive business days, culminating on September 3, 2024. This development is favorable for RedHill, which focuses on gastrointestinal and infectious diseases, and is crucial for its financial positioning and investor confidence.
Read more →RDHLNew Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
RedHill Biopharma announced the peer-reviewed publication of a Phase 2/3 study analyzing the efficacy of opaganib in treating COVID-19 pneumonia. The study revealed that oral opaganib treatment resulted in a 62% reduction in mortality and a 21% faster recovery without supplemental oxygen for patients requiring a fraction of inspired oxygen. The research suggests that a FiO2 level above 60% may serve as a biomarker for selecting patients with severe disease. The findings underscore the potential of opaganib as a new oral therapy while highlighting ongoing treatment challenges for hospitalized COVID-19 patients.
Read more →RDHLRedHill Biopharma Announces First Half 2024 Business Highlights
RedHill Biopharma reported its first half 2024 business highlights, showcasing a strengthened cash balance and operational efficiency following the termination of its agreement with Movantik Acquisition Co. The company emphasized a promising pipeline supported by U.S. government collaborations, addressing underserved indications across various therapeutic areas. Despite a decrease in net revenues for Talicia and ongoing challenges from previous setbacks, positive clinical results and a streamlined organization indicate potential for future growth.
Read more →RDHLRedHill Biopharma Announces First Half 2024 Business Highlights A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following the Termination Agreement
RedHill Biopharma has reported its first half 2024 financial results, showcasing a notable transformation in the company's operations. While net revenues fell to $2.6 million from $5.4 million the prior year, the company has strengthened its cash balance and development pipeline. The CEO highlighted the successful implementation of cost-cutting measures and projected upcoming catalysts in drug development aimed at addressing significant medical needs. Despite facing a net loss, RedHill remains focused on enhancing its operational efficiency and market position.
Read more →RDHL▼ -6.5%on this newsshared move
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to...
RedHill Biopharma has announced that the FDA has granted Orphan Drug designation to its investigational drug opaganib for the treatment of neuroblastoma, the most common cancer in infants. This designation allows for seven years of marketing exclusivity if opaganib receives approval, alongside potential benefits like accelerated review times and funding opportunities. The neuroblastoma market is expected to grow significantly, reaching almost $1.5 billion before the mid-2030s. Opaganib is the second orphan drug designation the company has received in oncology, following a previous designation for cholangiocarcinoma.
Read more →RDHL▲ +25.1%on this newsshared move
Talicia® Launched in the United Arab Emirates
RedHill Biopharma has launched Talicia, an all-in-one combination treatment for H. pylori infections, in the United Arab Emirates. This launch not only expands access to a highly effective therapy but also qualifies RedHill for additional financial incentives including milestone payments and royalties. Talicia is the first approved low-dose rifabutin-containing therapy in the region and is positioned to meet significant medical needs given the high prevalence of H. pylori infections in the UAE. The drug has demonstrated strong efficacy in clinical studies, addressing issues of antibiotic resistance in conventional treatments.
Read more →RDHL▲ +10.7%on this news· ran to +31% by day 3shared move
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
RedHill Biopharma announced promising results from studies involving opaganib, a novel oral drug aimed at obesity and diabetes management. Conducted by Apogee Biotechnology, the studies revealed that opaganib effectively suppressed weight gain and improved glucose tolerance in high-fat diet models. The findings suggest future clinical applications for opaganib in preventing and treating Type 2 diabetes and other obesity-related conditions. The company is also exploring additional collaborations and clinical developments for opaganib in various indications.
Read more →RDHL▼ -22.6%on this newsshared move
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
RedHill Biopharma Ltd. announced plans to change the ratio of its American Depositary Shares from 1 ADS representing 400 ordinary shares to 1 ADS representing 10,000 ordinary shares, effective around August 20, 2024. This change is designed to potentially increase the ADS price and help the company comply with Nasdaq's minimum bid price requirements. The depositary bank will handle the exchange process for existing ADS holders without requiring further action from them. The company's ongoing challenges regarding compliance with Nasdaq regulations and the success of its clinical programs remain critical points of focus.
Read more →RDHL▲ +97.9%on this news
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill
RedHill Biopharma announced positive data from a Phase 3 study showing that RHB-104, a triple antimicrobial therapy, achieved a 64% increase in efficacy over standard of care for patients with Crohn's disease. The study, published in the journal Antibiotics, involved 331 patients and confirmed the primary endpoint of clinical remission at week 26. RHB-104 was well tolerated and proved effective for patients receiving various concurrent treatments. These findings support the hypothesis linking Mycobacterium avium subspecies paratuberculosis to Crohn's disease.
Read more →RDHL▲ +5.1%on this news
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
RedHill Biopharma Ltd. has announced a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma, LLC, and HCR Redhill SPV, LLC, enhancing its financial standing by approximately $12.2 million. This agreement eliminates encumbrances related to previous credit ties and restores control over cash collections for the company. With this development, RedHill aims to focus on research and development activities and commercial prospects, marking a significant step towards returning to growth mode according to CFO Razi Ingber.
Read more →RDHLRedHill Biopharma Terminates License Agreement for Aemcolo®
RedHill Biopharma and Cosmo Technologies Ltd. have mutually decided to terminate their exclusive U.S. license agreement for the treatment Aemcolo, effective October 8, 2024. Following this decision, RedHill will cease all commercialization efforts for Aemcolo, and the rights will revert to Cosmo. RedHill's Chief Commercial Officer expressed appreciation for the partnership with Cosmo, highlighting a professional relationship. This termination raises concerns about the future product portfolio of RedHill, which currently has several key clinical programs underway.
Read more →RDHLRedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
RedHill Biopharma announced that a new Chinese patent has been granted for opaganib, allowing its use in combination with immune checkpoint inhibitors (ICIs) to enhance anti-cancer immune responses. This patent offers protection until 2040, contributing to the development of opaganib across various indicated uses, including oncology and viral applications. With the global ICI market projected to exceed $100 billion by 2028, the combination of opaganib with ICIs represents a significant advancement in cancer therapies. This comes as opaganib has demonstrated promising efficacy in clinical studies and a strong safety profile.
Read more →RDHLRedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill Biopharma has announced the issuance of a new Chinese patent for opaganib, a therapy targeting single-stranded RNA viruses, especially the Ebola virus. Valid until 2035, this patent strengthens the drug's global intellectual property portfolio. U.S. Army research indicates opaganib may be a pioneering host-directed molecule that improves survival rates in Ebola virus disease. Furthermore, opaganib displays a synergistic effect when paired with remdesivir, indicating its potential in treating viral infections.
Read more →RDHLRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
RedHill Biopharma has announced the enrollment of the first patient in the PROTECT trial, a Phase 2 study for its antiviral drug RHB-107 aimed at treating early COVID-19. This government-supported trial includes a global cohort of 300 patients and is expected to conclude by late 2024. RHB-107 has previously demonstrated promising outcomes, such as a complete reduction in hospitalization in a prior Phase 2 study. The company aims to provide an effective treatment option for COVID-19 independent of viral mutations.
Read more →RDHLRedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill Biopharma reported its full-year 2023 financial and operational highlights, showcasing a transformation towards a U.S. government-funded developmental pipeline focusing on significant therapeutic areas. Notable advancements include the selection of opaganib and RHB-107 for key U.S. military and health studies related to Ebola and COVID-19 treatments, with encouraging results in clinical trials. The company's financial performance improved substantially, marked by a net income of $23.9 million following the divestiture of Movantik, as it emphasizes cost-reduction measures and strategic business initiatives. RedHill continues to engage in discussions for potential asset divestment while focusing on the advancement of its lead candidates.
Read more →RDHLRedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
RedHill Biopharma Ltd. has announced a registered direct offering to raise $1.25 million by selling 2,144,487 American Depositary Shares (ADSs) at a price reflecting a 10% premium over its market closing price. The company intends to use the proceeds for general corporate purposes and working capital. The offering is expected to close on or about April 3, 2024. This action aims to bolster RedHill's financial position as it continues to develop its pipeline of therapeutic candidates.
Read more →RDHLRedHill Announces New USPTO Patent Covering Talicia® Through 2034
RedHill Biopharma announced that the U.S. Patent and Trademark Office has granted a new patent for Talicia, an all-in-one treatment for Helicobacter pylori, which will protect the product until February 12, 2034. Talicia is positioned as the only FDA-approved rifabutin-containing therapy for this infection, which affects about 35% of the U.S. adult population. The patent enhances RedHill's robust intellectual property surrounding Talicia, bolstering its market presence and exclusivity. The drug is recognized for its optimized antibiotic resistance profile, addressing the growing concern of resistance in H. pylori treatments.
Read more →RDHL▼ -7.5%on this news
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively...
RedHill Biopharma's investigational drug, opaganib, has been selected by the U.S. government's Chemical Medical Countermeasures Program and the Chemical Countermeasures Research Program for evaluation as a potential countermeasure against Sulfur Mustard exposure. This selection follows opaganib's earlier acceptance into the Radiation and Nuclear Countermeasures Program for Acute Radiation Syndrome. The drug is noted for its oral administration, potential broad efficacy, and ease of distribution, provided it receives FDA approval. Opaganib is also being developed for additional indications including COVID-19 and oncology.
Read more →RDHLRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in...
RedHill Biopharma announced positive findings on opaganib, showing it significantly improves long-term survival in an in vivo model of lung damage caused by ionizing radiation. The data, published in the International Journal of Molecular Sciences, indicates opaganib's potential as a medical countermeasure for acute radiation syndrome and other indications. Furthermore, opaganib is being tested for various diseases and has been selected for the NIH's Radiation and Nuclear Countermeasures Product Development Program, highlighting its broad therapeutic potential.
Read more →RDHLRedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
RedHill Biopharma Ltd. has completed an $8 million registered direct offering for 10 million American Depositary Shares (ADSs) at $0.80 per share. Additionally, the company issued unregistered warrants for the purchase of up to 10 million ADSs. The proceeds will be allocated towards general working capital, acquisitions, and research and development. H.C. Wainwright & Co. acted as the exclusive placement agent for this transaction.
Read more →RDHL▼ -39.9%on this newsshared move
RedHill Biopharma Announces $8 Million Registered Direct Offering
RedHill Biopharma has announced a registered direct offering, raising $8 million by selling 10 million American Depositary Shares (ADSs) at $0.80 each. The financing includes unregistered warrants with a five-year term and an exercise price of $1.00 per ADS. The funds are intended for general working capital, research and development, and corporate purposes. The closing of this offering is expected to occur around January 29, 2024, pending customary closing conditions.
Read more →RDHL▼ -39.9%on this newsshared move
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
RedHill Biopharma announced that the USPTO granted a new patent for Talicia, extending its protection against H. pylori treatment until May 2042. The patent underscores Talicia's efficacy, which remains effective regardless of patient BMI, responding to rising obesity rates in the U.S. Recently, the FDA also afforded Talicia five years of market exclusivity under the GAIN Act QIDP designation, further strengthening its position in the market. Talicia is recognized as a leading first-line therapy for eradicating H. pylori, a prevalent bacterial infection in the U.S.
Read more →RDHL▲ +6.1%on this news
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
RedHill Biopharma has announced promising results from a U.S. Army-funded study showing that its investigational drugs opaganib and RHB-107 work synergistically with remdesivir to inhibit the Ebola virus. This combination significantly improves potency while maintaining cell viability. Additionally, opaganib is noted to be the first host-directed molecule with efficacy against Ebola, and both drugs have demonstrated potential effectiveness against other viral infections, including COVID-19. These findings support further research into their use as therapeutic options for Ebola virus disease.
Read more →RDHL▲ +13.9%on this news
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
RedHill Biopharma has announced new non-dilutive external funding of approximately $4.8 million for its RHB-107 (upamostat) Phase 2 study in early COVID-19 outpatient treatment. The study, which has received FDA clearance, aims to assess the drug's safety and efficacy across multiple countries, with an estimated completion date by the end of 2024. Previous studies indicated that RHB-107 could significantly reduce hospitalizations due to COVID-19, highlighting its potential as an effective antiviral treatment. The company positions RHB-107 as a crucial player in the early COVID-19 treatment market, aiming to offer an alternative to existing therapies.
Read more →RDHL▲ +217%on this news· ran to +623% by day 1
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
RedHill Biopharma announced that the U.S. FDA has granted Talicia five years of market exclusivity under the GAIN Act QIDP designation. This exclusivity is in addition to the three years previously granted following its approval. Talicia, aimed at eradicating H. pylori infection, is notable for being the only FDA-approved rifabutin-based therapy and is now supported by a flexible dosing regimen to enhance patient adherence. The product is protected by an extensive intellectual property suite until 2034.
Read more →RDHL▲ +9%on this news
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
RedHill Biopharma has announced its transfer of listing to the Nasdaq Capital Market following a compliance issue with the Nasdaq Global Market. The transfer, effective November 15, 2023, allows trading under the same ticker symbol 'RDHL' without interruption. This decision was made after the company received a notification regarding its failure to meet Nasdaq's Market Value of Publicly Held Shares (MVPHS) requirement, leaving them until March 2024 to demonstrate compliance. The company continues its focus on developing treatments for gastrointestinal and infectious diseases.
Read more →RDHL▼ -14.9%on this news
RedHill and U.S. Army Announce Opaganib
RedHill Biopharma announced that its investigational drug opaganib has shown a statistically significant increase in survival time in a U.S. Army-funded study focusing on Ebola virus disease. Opaganib is noted as the first host-directed molecule to exhibit such activity and has previously demonstrated efficacy against COVID-19. The study involved administering opaganib at various doses, with the 150 mg/kg group achieving significant results. Further investigations into its antiviral potential are anticipated, particularly given the urgent need for effective therapies against Ebola and other viral infections.
Read more →RDHLRedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
RedHill Biopharma has received a notification from Nasdaq indicating that its American Depositary Shares (ADSs) closed below the minimum bid price requirement of $1.00 for thirty consecutive business days. The company is granted an initial 180-day period to regain compliance, which lasts until March 18, 2024. While trading remains unimpacted, the company faces additional challenges, as it is also not in compliance with Nasdaq's minimum MVPHS requirement and may be subject to delisting by November 6, 2023, if corrective measures are not taken.
Read more →RDHLRedHill Announces FDA sNDA Approval for Talicia®
RedHill Biopharma announced the FDA's approval of a supplemental new drug application for Talicia, allowing for a simplified three times daily dosing regimen to enhance adherence in H. pylori eradication. This new regimen replaces the previously required dosing regimen of every eight hours, facilitating a more manageable treatment schedule. Talicia remains a unique offering as the only FDA-approved rifabutin-based therapy and has shown promising clinical outcomes, including improved eradication rates of H. pylori. Market exclusivity and patent protections extend into 2034, highlighting the product's strategic significance for RedHill.
Read more →RDHLRedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
RedHill Biopharma announced a new patent allowance from the USPTO for opaganib, which targets sphingosine kinase 2 inhibition for Ebola virus treatment, extending its patent protection until October 2035. Additionally, the European Patent Office granted a patent for RHB-102, covering ondansetron extended-release forms for treating gastrointestinal symptoms, valid until March 2035. The news supports RedHill's strategic position and enhances the potential for its product pipeline, particularly with RHB-102 showing positive results in clinical studies.
Read more →RDHL▲ +13.4%on this news
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
RedHill Biopharma has reported its financial results for the first half of 2023, indicating a transition towards a debt-free structure with reduced operational costs. The company's lead candidates, RHB-107 and opaganib, are advancing with extensive support from U.S. government funding, including trials for COVID-19 and gastrointestinal acute radiation syndrome. Despite achieving a net income of $51 million, the company experienced a notable decline in revenues due to the divestiture of Movantik, affecting overall asset and revenue figures compared to the previous year.
Read more →RDHL▲ +13.4%on this news
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights RHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpa
RedHill Biopharma announced its financial results for the first half of 2023, noting progress in R&D with RHB-107 and opaganib. The company reported a decrease in net revenues due to the divestiture of Movantik but is now debt-free and has reduced its cost structure. RHB-107 has been accepted into a key early COVID-19 treatment trial supported by the U.S. Department of Defense, while opaganib has garnered further government funding. Despite challenges reflected in financial metrics, the firm aims to strengthen its balance sheet through asset divestment discussions.
Read more →RDHLRedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
RedHill Biopharma announced that its partner, Gaelan Medical, has received marketing approval from the UAE Ministry of Health for Talicia, a novel treatment for H. pylori. This approval makes Talicia the first rifabutin-containing combination product approved in the UAE. Gaelan Medical has also placed a significant initial order, signaling the start of commercialization activities. The introduction of Talicia is particularly vital given the public health concerns surrounding H. pylori infections in the region.
Read more →RDHLRedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA RHB-107 (upamostat) accepted for inclusion in ACESO's PROTECT adaptive platform trial for early COVID-19 outpatient treatment to be conducted in the...
RedHill Biopharma's RHB-107 (upamostat) has been accepted into the PROTECT adaptive platform trial for early outpatient COVID-19 treatment, backed by the U.S. government. The Phase 2 study, with 300 patients, has received FDA clearance and is expected to start in Q3 2023, concluding by the end of 2024. RHB-107 has shown significant safety and efficacy in earlier trials, including a complete reduction in hospitalization rates. If successful, it could address the growing need for effective early treatment options amidst evolving COVID-19 variants.
Read more →RDHL▼ -25.9%on this news
RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
RedHill Biopharma announced an additional $1.7 million in U.S. Government funding for the development of opaganib as a medical countermeasure against gastrointestinal acute radiation syndrome (ARS). This funding, awarded through a Small Business Innovation Research (SBIR) grant to their development partner Apogee, complements existing multimillion-dollar contracts from the U.S. Government's Radiation and Nuclear Countermeasures Program. Opaganib's development benefits from prior FDA confirmation regarding its regulatory pathway, increasing expectations for its approval and stockpiling for potential nuclear incidents.
Read more →RDHLRedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
RedHill Biopharma reported strong financial results for Q1 2023, achieving a net income of $50.2 million largely due to the sale of Movantik. The company plans to focus on maximizing revenues from Talicia and advancing the development of RHB-107 and opaganib. However, it faced a notable decrease in net revenues attributed to the Movantik divestiture and received a non-compliance notice regarding Nasdaq listing requirements, which may affect its stock stability. Overall, RedHill is realigning its operations and focusing on promising R&D projects while navigating financial challenges.
Read more →RDHLRedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week
RedHill Biopharma recently announced new data for Talicia, showing that generically substituted regimens are non-bioequivalent to the branded product. Presented at Digestive Disease Week, the data also indicated that Talicia's TID dosing is bioequivalent to Q8H dosing, which could enhance patient adherence. Talicia is currently recognized as the leading prescribed therapy for eradicating H. pylori, a prevalent bacterial infection in the U.S. adult population.
Read more →RDHL▼ -8%on this news
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting RedHill Biopharma Ltd. (NASDAQ: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced the granting of two new EU ...
RedHill Biopharma Ltd. announced today that it has been granted new patents for RHB-102 (BEKINDA) and opaganib in the oncology sector. The European Patent Office's grant for RHB-102 covers an extended-release antiemetic formulation, while the U.S. Patent and Trademark Office granted a patent for opaganib regarding cancer combination therapies. Both patents provide extended protection for their respective drugs, offering RedHill potential market opportunities and support for further developments in treating various conditions, including chemotherapy-induced nausea and vomiting. The company is engaging with potential commercialization partners as it seeks to advance its therapeutic candidates.
Read more →RDHL▲ +6.6%on this newsshared move
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
RedHill Biopharma reported its Q4 2022 and full-year results, highlighting a turnaround with a debt-free status and significant cost reductions. The company noted a 57% increase in Talicia prescriptions and is moving forward with its late-stage pipeline, particularly opaganib, which has been selected for testing by the NIH. Financial results showed reduced revenues from previous years primarily due to gross-to-net allowances, despite overall operational improvements.
Read more →RDHL▼ -6.3%on this news· ran to -26% by day 3
RedHill Biopharma Announces $6 Million Registered Direct Offering
RedHill Biopharma has announced a $6 million registered direct offering of its American Depositary Shares (ADSs) and associated warrants. The proceeds are intended for general working capital, acquisitions, and research and development. The offering is set to close around April 3, 2023, subject to conditions. Additionally, the company is amending existing warrants to reduce exercise prices, which suggests adjustments in their financial strategy.
Read more →RDHLRedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders
RedHill Biopharma has launched a warranty program for its H. pylori treatment Talicia, promising reimbursement for patients whose infection is not eradicated after completing the full treatment course. Reportedly the first of its kind for a community-treated condition, this initiative aims to increase patient access to a therapy boasting over a 90% cure rate. Talicia, recognized as the leading prescribed H. pylori therapy among U.S. gastroenterologists, addresses the rising resistance to traditional treatments. The program extends to all commercially insured and non-insured patients, signifying RedHill's commitment to enhancing treatment accessibility.
Read more →RDHLRedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
RedHill Biopharma has announced a definitive agreement for a private placement of up to $6 million with a single investor. This includes the issuance of convertible promissory notes and warrants that will be utilized for general working capital, acquisitions, and research and development. The funding will be disbursed in three tranches with specific conditions tied to regulatory filings. This structured financing may enhance RedHill's capabilities in the pharmaceutical space, particularly in gastrointestinal and infectious diseases.
Read more →RDHLRedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program The National Institutes of Health's (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for testing via their radiation...
RedHill Biopharma's drug opaganib has been selected by the NIH's Radiation and Nuclear Countermeasures Program for testing as a potential treatment for Acute Radiation Syndrome (ARS). This collaboration will validate opaganib's efficacy in pre-clinical models of ARS, with research support expected to enhance the development program. The selection follows recent FDA guidance regarding the Animal Rule regulatory pathway for opaganib, allowing studies to utilize animal model efficacy instead of human trials. Opaganib is noted for its ease of administration and potential stockpiling for mass casualty incidents.
Read more →RDHLRedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
RedHill Biopharma announced a positive outcome from a meeting with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regarding its RHB-102 (Bekinda) drug. The company plans to submit a Marketing Authorisation Application (MAA) in the second half of 2023, aiming to position RHB-102 as the first oral 24-hour extended-release antiemetic for chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV) in the UK. The drug has shown promise in clinical studies, particularly in the management of nausea related to cancer therapies.
Read more →RDHLRedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
RedHill Biopharma expressed positive results from its recent FDA meeting regarding opaganib, aimed at treating Acute Radiation Syndrome (ARS). The FDA provided guidance on utilizing pivotal animal model studies to support regulatory approval under the Animal Rule, which is applicable when human trials are not ethical. The company plans to collaborate with the FDA and various U.S. agencies to advance opaganib as a medical countermeasure. This oral medication may potentially be stockpiled by governments for mass casualty nuclear incidents.
Read more →RDHLRedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill
RedHill Biopharma has announced the extinguishment of all debt obligations through an agreement with HealthCare Royalty, which involves the transfer of rights to its drug Movantik. As a result, RedHill will remain free of debt liabilities and can focus on expanding its revenue-generating products. The company will provide transition services to ensure continuous patient care. CEO Dror Ben-Asher expressed optimism about RedHill's future as a debt-free entity, highlighting plans to maximize existing products and advance its late-stage pipeline.
Read more →RDHLRedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
RedHill Biopharma announced that it has received a Notice of Allowance from the USPTO for a patent related to RHB-204, an oral fixed-dose combination drug intended for the treatment of non-tuberculosis mycobacterial (NTM) disease caused by Mycobacterium avium complex infection. This patent could extend RHB-204's protection until 2041. RHB-204 is currently undergoing a Phase 3 clinical trial in the U.S. and has received multiple designations from the FDA and EMA, signifying its potential in treating a disease that currently lacks approved first-line therapies.
Read more →RDHL▲ +26.2%on this news
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
RedHill Biopharma announced positive results from a Phase 2 study of RHB-107 for non-hospitalized symptomatic COVID-19 patients, published in the International Journal of Infectious Diseases. The study showed that RHB-107 achieved a primary endpoint of safety and tolerability, and provided significant efficacy data, including a 100% reduction in hospitalization rates and faster recovery from severe symptoms. Discussions for further development, including a Phase 3 study and potential additional funding, are underway as the drug showcases promise against emerging viral variants.
Read more →RDHLRedHill Biopharma Prices $8.0 Million Underwritten Public Offering
TEL AVIV, Israel, and RALEIGH, N.C., Dec. 2, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected
Read more →RDHLRedHill Biopharma Announces Proposed Public Offering
TEL AVIV, Israel and RALEIGH, N.C., Dec. 1, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions American Depositar
Read more →RDHLRedHill Biopharma Announces Q3/22 Results and Operational Highlights
Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth Q3/22 Net revenues of $17.6 million; Operating loss of $7.1 million; Q3/22 positive cash flow from U.S. commercial operations, before interest payment
Read more →RDHLRedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
Positive in vivo results from a new study of opaganib in radiation-induced hematologic and renal toxicity reaffirms opaganib's potential protective impact on hematological and kidney function following total body irradiation (TBI) These new preclinical results are consistent wit
Read more →RDHLRedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik®
TEL AVIV, Israel and RALEIGH, N.C., Nov. 14, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has reached a non-binding agreement in principle with HCR Collateral Management, LL
Read more →RDHLRedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22: Net revenues of $13.1 million; Q3/22: Net revenues estimated[2] to be between $16.5million to $18.5 million; Operating los
Read more →RDHLRedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates Financial update : Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance 1 of $43.2 million as of
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance1 of $43.2 million as of June 30, 2022; Restated Q1/22: Net revenues of $13.1 million; Q3/22: Net revenues estimated2 to be
Read more →RDHLRedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022
Physiologically-Based Pharmacokinetic (PBPK) modeling study of Talicia evaluated intragastric antibiotic exposure, critical for successful H. pylori eradication, comparing low-dose rifabutin 50 mg every 8 hours to generic rifabutin triple therapy 150mg twice a day or 300 mg once
Read more →RDHLRedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and receiving supplemental ...
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and receiving supplemental oxygen at a fraction of inspired oxygen (FiO2) up to and including 60% Previous variant-agnostic efficacy data for opaganib, an i
Read more →RDHLRedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections
Developed as the first stand-alone standard of care first-line therapy for NTM disease caused by Mycobacterium avium complex (MAC) infection, RHB-204 is currently undergoing a Phase 3 study in the U.S. EMA Orphan Drug Designation provides eligibility for 10 years post-approval E
Read more →RDHLRedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences
Talicia® - World Gastro 2022 congress (August 17-18): RedHill invited to give prestigious oral presentation of important data detailing high eradication rates across body mass index (BMI) groups with Talicia, the U.S.'s leading brand for Helicobacter pylori (H. pylori) eradicatio
Read more →RDHLRedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 mon
Read more →RDHLRedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022
TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on
Read more →RDHLRedHill Presents New Talicia® Data Analyses at DDW 2022
Talicia's efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population associated with sub-optimal outcomes with clarithromycin-based H. pylori eradication therapy Physiologically based pharmacokinet
Read more →RDHLRedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
TEL AVIV, Israel and RALEIGH, N.C, May 9, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement with a single leading healthcare investor for
Read more →RDHLRedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro
- Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, a world renowned WHO collabo
Read more →RDHLRedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results
TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational highlights and financial results for the fourth quarter and full year ended
Read more →RDHLRedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea
TEL-AVIV, Israel, and RALEIGH, N.C., March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd. (Kospi: 001140) ("K
Read more →RDHLRedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on March 17, 2022
TEL AVIV, Israel and RALEIGH, NC, March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results and operational
Read more →RDHLRedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
TEL AVIV, Israel and RALEIGH, N.C., March 1, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral R
Read more →RDHLRedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven
TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided a business update for the fourth quarter of 2021, including certain estimated unaudited prel
Read more →RDHLRedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates
RALEIGH, N.C. and TEL-AVIV, Israel, Jan. 6, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Gaelan Medical Trade LLC ("Gaelan Med
Read more →RDHLRedHill Biopharma Announces Additional Insider Buying
RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 15, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chair
Read more →RDHLRedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication
RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the publication in the journal Digestive Diseases and Sciences of a new study entitled "Pitf
Read more →RDHLRedHill Biopharma Opaganib Wirkmechanismus wird durch Mutationen im viralen Spike-Protein, einschließlich der Omikron-Mutationen, nicht beeinflusst
Einzigartiger Wirkmechanismus Opaganib wirkt, indem es direkt auf die menschliche Wirtszelle und nicht auf das Virus selbst abzielt, so dass keine Beeinflussungen durch Spike-Protein-Mutationen erwartet werden, was für sein großes Potenzial zur Bekämpfung der SARS-CoV-2-Variante
Read more →RDHLRedHill Biopharma informa que o mecanismo do opaganibe não foi impactado por mutações na proteína spike do vírus, incluindo mutações da Ômicron
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 8 de dezembro de 2021 /PRNewswire/ -- Modo de ação exclusivo O opaganibe atua tendo como alvo a célula hospedeira humana, e não o próprio vírus, e portanto não se espera que seja impactado por mutações na proteína spike, proporcion
Read more →RDHLRedHill Biopharma informa que el mecanismo de acción del opaganib no se ve afectado por mutaciones virales de la proteína de espiga, incluidas las mutaciones de la variante ómicron
TEL AVIV, Israel, y RALEIGH, Carolina del Norte, 8 de diciembre de 2021 /PRNewswire/ -- Modo de acción único El opaganib actúa dirigiéndose a la célula huésped humana en lugar de al virus en sí y, por lo tanto, no se espera que se vea afectado por mutaciones en la proteína de e
Read more →RDHLRedHill Biopharma informa que el mecanismo de Opaganib no se ve afectado por mutaciones de Ómicron
- RedHill Biopharma informa que el mecanismo de Opaganib no se ve afectado por mutaciones virales de proteína de pico, incluidas mutaciones de Ómicron TEL AVIV, Israel y RALEIGH, N.C., 8 de diciembre de 2021 /PRNewswire/ -- Modo de acción único Opaganib actúa dirigiéndose a la
Read more →RDHLRedHill Biopharma révèle que les mutations dans la protéine Spike (et les mutations du variant Omicron) n
Mode d'action unique L'opaganib fonctionne en ciblant les cellules hôtes humaines et non le virus lui-même. C'est pourquoi son mécanisme ne devrait pas être affecté par les mutations de la protéine Spike, justifiant ainsi son potentiel pour lutter contre le variant Omicron du SA
Read more →RDHLRedHill Biopharma informa aspectos operacionales destacados y resultados financieros del tercer trimestre de 2021
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 6 de diciembre de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" o la "Compañía"), una compañía biofarmacéutica especializada, presentó hoy sus resultados financieros y aspectos operacionales destacados del te
Read more →RDHLRedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations
Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other
Read more →RDHLRedHill Biopharma informa destaques operacionais e resultados financeiros do terceiro trimestre de 2021
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 6 de dezembro de 2021 /PRNewswire/ -- A empresa biofarmacêutica especializada RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" ou a "Empresa") divulgou hoje seus resultados financeiros e destaques operacionais do segundo trimestre, q
Read more →RDHLRedHill Biopharma présente ses faits saillants opérationnels et ses résultats financiers pour le troisième trimestre de 2021
RedHill accélère ses deux programmes cliniques avancés de comprimés destinés à traiter le COVID-19 à la lumière de leur efficacité potentielle contre le variant Omicron Agissant indépendamment de la mutation de la protéine transitoire, les mécanismes d'action uniques de ciblage
Read more →RDHLRedHill Biopharma meldet operative Highlights und Finanzergebnisse für das dritte Quartal 2021
RedHill beschleunigt die Entwicklung seiner beiden fortgeschrittenen klinischen COVID-19-Programme im Hinblick auf ihr Potenzial als Tablette gegen Omicron Opaganib und RHB-107 wirken aufgrund ihrer einzigartigen, auf den Wirt ausgerichteten Wirkmechanismen, unabhängig von einer
Read more →RDHLRedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announces the publication of a new study entitled "Helicobacter pylori Eradication by Low-Dose Rifabutin Tri
Read more →RDHLRedHill Biopharma:Resultados operativos y financieros del tercer trimestre de 2021
- RedHill Biopharma informa de los aspectos operativos más destacados y de los resultados financieros del tercer trimestre de 2021 RedHill acelera sus dos programas clínicos avanzados de la píldora de la COVID-19 a la luz de su potencial contra Ómicron Actuando independientemen
Read more →RDHLRedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation, opaganib and RHB-107's unique host-targeted mechanisms of action hold potential versus Omicron and other variants --
Read more →RDHLRedHill Biopharma to Host Third Quarter 2021 Financial Results and Operational Highlights Webcast on November 30, 2021
TEL AVIV, Israel and RALEIGH, N.C., Nov. 24, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its third quarter 2021 financial results and operational highlights on
Read more →RDHLRedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of the previously announced underwritten public offering of approximately 4.7 m
Read more →RDHLRedHill Biopharma Announces Pricing of $15.5 Million Public Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C., Nov. 19, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the pricing of an underwritten public offering of 4.7 million American Depositary Shares ("
Read more →RDHLRedHill Biopharma Announces Underwritten Public Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C., Nov. 18, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced an underwritten public offering of American Depositary Shares ("ADSs"). Each ADS represents
Read more →RDHLRedHill Biopharma anuncia el último paciente aleatorizado en la parte A del estudio COVID-19
- RedHill Biopharma anuncia el último paciente aleatorizado en la parte A del estudio COVID-19 de fase 2/3 en curso de RHB-107 oral de una sola toma al día en pacientes no hospitalizados - Finaliza el reclutamiento para la Parte A del estudio de Fase 2/3 de RHB-107 (upamostat) a
Read more →RDHLRedHill Biopharma gibt die ambulante Behandlung des letzten Patienten im Teil A der laufenden COVID-19-Phase-2/3-Studie mit einmal täglich oral einzunehmenden RHB-107 bekannt
Patientenrekrutierung für den Teil A der Phase-2/3-Studie mit einmal täglich oral verabreichtem RHB-107 (Upamostat) für Patienten mit symptomatischer COVID-19, die keine Krankenhausbehandlung benötigen, abgeschlossen Top-Line-Ergebnisse für den Teil A der Studie zur Dosisfindung
Read more →RDHLRedHill Biopharma Annonce Que le Dernier Patient a Été Aléatoirement Sélectionné Dans la Partie A de L
- Recrutement terminé pour la partie A de l'étude de phase 2/3 du RHB-107 (upamostat) administré une fois par jour par voie orale pour les patients présentant des symptômes de COVID-19 et ne nécessitant pas de soins hospitaliers - Les premiers résultats de la partie A de l'étude
Read more →RDHLRedHill Biopharma anuncia último paciente randomizado na Parte A do estudo de Fase 2/3 da COVID-19 em andamento do RHB-107 administrado por via oral uma vez ao dia em pacientes não hospitalizados
- Foi concluído o recrutamento da Parte A do estudo de Fase 2/3 do RHB-107 (upamostat) administrado por via oral uma vez ao dia para pacientes com COVID-19 sintomática que não precisam de assistência hospitalar - Resultados de primeira linha da Parte A do estudo, desenvolvido pa
Read more →RDHLRedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB
Read more →RDHLRedHill Biopharma et la société sud-coréenne Kukbo Co. annoncent un investissement stratégique dans la société RedHill pouvant atteindre 10 millions de dollars
RedHill a reçu la première tranche de 5 millions de dollars dans un placement privé d'actions restreintes au prix de 6,04 $ par ADS, ce qui représente une prime de 20 % basée sur le prix moyen pondéré en fonction du volume (VWAP) de 30 jours de bourse se terminant à la date d'ent
Read more →RDHLRedHill Biopharma und das südkoreanische Unternehmen Kukbo Co. kündigen eine strategische Investition von bis zu $10 Millionen in RedHill an
RedHill erhielt die erste Tranche von $5 Mio. im Rahmen einer Privatplatzierung von Aktien mit Verfügungsbeschränkung zu einem Preis von $6,04 pro ADS, was einem Aufschlag von 20% auf der Grundlage des volumengewichteten Durchschnittspreises (VWAP) der letzten 30 Handelstage am S
Read more →RDHLRedHill Biopharma e Kukbo Co. da Coreia do Sul anunciam investimento estratégico de até dez milhões de dólares na RedHill
A RedHill recebeu a primeira parcela de cinco milhões de dólares em uma colocação privada de ações restritas a 6,04 de dólares por ADS, representando um prêmio de 20% com base no preço médio ponderado por volume (VWAP) de 30 dias de negociação, que termina na data de vigência A
Read more →RDHLRedHill Biopharma y Kukbo Co. de Corea del Sur anuncian una inversión estratégica de hasta USD 10 millones en RedHill
RedHill recibió el primer tramo de USD 5 millones en una colocación privada de acciones restringidas a un precio de USD 6,04 por ADS, lo que representa una prima del 20 % basada en el precio promedio ponderado por volumen (VWAP) de 30 días de cotización finalizado en la fecha de
Read more →RDHLKukbo Co. invierte hasta 10 millones de dólares en RedHill
-RedHill Biopharma y la surcoreana Kukbo Co. anuncian una inversión estratégica de hasta 10 millones de dólares en RedHill RedHill recibió el primer tramo de 5 millones de dólares en una colocación privada de acciones restringidas a un precio de 6,04 dólares por ADS, lo que repr
Read more →RDHLRedHill Biopharma to Present at H.C. Wainwright 7th Annual Israel Conference and German Equity Forum (EKF) 2021
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg, RedHill's Chief Business Officer, will present an overview of the Com
Read more →RDHLRedHill Biopharma and South Korea
TEL AVIV, Israel and RALEIGH, NC, Nov. 8, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a strategic agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"),
Read more →RDHLRedHill Biopharma Presents New Talicia® and Movantik® Data Analyses at ACG 2021
TEL AVIV, Israel and RALEIGH, N.C., Oct. 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the presentation of four new analyses of Phase 3 Talicia® (omeprazole magnesium, amoxicilli
Read more →RDHLRedHill Biopharma to Present at the BIO-Europe 2021 Conference
TEL AVIV, Israel and RALEIGH, N.C. , Oct. 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill's Chief Corporate & Business Development Officer, will present
Read more →RDHLRedHill Biopharma Announces Insider Buying
TEL-AVIV, Israel & RALEIGH, N.C, Oct. 18, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chairman
Read more →RDHLRedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034
TEL AVIV, Israel and RALEIGH, N.C., Oct. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the granting of U.S. Patent No. 11,135,172 covering Talicia, its U.S. approved medicine ind
Read more →RDHLRedHill Biopharma présente une analyse plus approfondie des données de la phase 2/3 comprenant une réduction de 62 % de la mortalité avec l
Réduction statistiquement significative de 62 % de la mortalité dans le groupe de patients atteints de COVID-19 modérément grave et traités à l'opaganib par rapport au groupe contrôlé par placebo (7 décès dans le groupe opaganib de 117 patients contre 21 décès dans le groupe plac
Read more →RDHLRedHill Biopharma informa análise adicional de dados de Fase 2/3 incluindo redução de 62% na mortalidade com opaganibe administrado por via oral em pacientes com COVID-19 de gravidade moderada
62% de redução estatisticamente significativa na mortalidade demonstrada no grupo de pacientes com COVID-19 de gravidade moderada tratados com opaganibe em comparação com o grupo controlado por placebo (sete mortes no grupo de 117 pacientes tratados com opaganibe em comparação co
Read more →RDHLRedHill Biopharma informa nuevos análisis de datos de fase 2/3 que incluye una reducción del 62 % en la mortalidad con opaganib oral en pacientes con COVID-19 moderadamente grave
Se evidenció un 62 % de reducción estadísticamente significativa de la mortalidad en pacientes con COVID-19 moderadamente grave tratados con opaganib en comparación con el grupo controlado con placebo (7 muertes en el grupo de 117 pacientes tratado con opaganib frente a 21 muerte
Read more →RDHLRedHill gibt zusätzliche Analyse der Phase-2/3-Ergebnisse mit oral verabreichtem Opaganib bekannt, die u.a. Reduzierung der Sterblichkeit um 62% bei COVID-19-Patienten mit mittelschwerem Krankheitsverlauf zeigt
Statistisch signifikante Reduzierung der Sterblichkeit um 62% in der Gruppe der COVID-19-Patienten mit mittelschwerem Krankheitsverlauf, die mit Opaganib behandelt wurden, gegenüber dem Placebo-Arm (7 Todesfälle in der Opaganib-Gruppe mit 117 Patienten gegenüber 21 Todesfällen in
Read more →RDHLRedHill Biopharma informa un análisis adicional de los datos de la fase 2/3
- RedHill Biopharma informa un análisis adicional de los datos de la fase 2/3, incluyendo una reducción del 62% en la mortalidad con Opaganib oral en pacientes que padecen COVID-19 moderadamente grave 62% de reducción estadísticamente significativa en la mortalidad mostrada para
Read more →RDHLRedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patients with severe COVID-
Read more →RDHLRedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo
TEL AVIV, Israel and RALEIGH, N.C., Sept. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZene
Read more →RDHLSuite à l'approbation des autorités sud-africaines, RedHill Biopharma accélère son étude de phase 2/3 en cours aux États-Unis portant sur la COVID-19 et l'administration orale d'une dose quotidienne unique du RHB-107 pour les patients non hospitalisés L'Autorité sud-africaine de réglementation des produits de santé (SAHPRA) a approuvé l'étude de phase 2/3 portant sur l'administration orale d'une...
L'Autorité sud-africaine de réglementation des produits de santé (SAHPRA) a approuvé l'étude de phase 2/3 portant sur l'administration orale d'une dose quotidienne unique du RHB-107 (upamostat) pour les patients atteints d'une forme symptomatique de COVID-19, mais qui n'ont pas b
Read more →RDHLRedHill Biopharma erweitert seine laufende US-amerikanische Phase 2/3 COVID-19-Studie mit einmal täglich oral einzunehmendem RHB-107 zur ambulanten Behandlung mit südafrikanischer Zulassung
Die südafrikanische Zulassungsbehörde „South African Health Products Regulatory Authority" (SAHPRA) hat die Phase 2/3 Studie mit einmal täglich oral verabreichtem RHB-107 (Upamostat) für die ambulante Behandlung von Patienten mit symptomatischer COVID-19 genehmigt Darüber hinaus
Read more →RDHLRedHill Biopharma acelera el estudio de COVID-19 de fase 2/3 en curso en los Estados Unidos con RHB-107 oral una vez al día en pacientes no hospitalizados con aprobación de Sudáfrica
La Autoridad Reguladora de Productos Sanitarios de Sudáfrica (SAHPRA) aprobó el estudio de fase 2/3 del RHB-107 (upamostat), que se administra por vía oral una vez al día en pacientes con COVID-19 sintomática que no requieren atención hospitalaria También se amplió la cantidad d
Read more →RDHLRedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH, NC, Sept. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary top-line data from the 475-patient global Phase 2/3 study with opaganib (ABC2946
Read more →RDHLRedHill Biopharma acelera el estudio actual de fase 2/3 COVID-19 de RHB-107
- RedHill Biopharma acelera el estudio actual de fase 2/3 COVID-19 de RHB-107 oral de una sola toma al día en pacientes no hospitalizados con aprobación sudafricana La Autoridad Normativa de Productos Sanitarios de Sudáfrica (SAHPRA) aprobó el estudio de fase 2/3 de RHB-107 (upa
Read more →RDHLRedHill Biopharma acelera estudo de Fase 2/3 da COVID-19 em andamento nos EUA do RHB-107 administrado por via oral uma vez ao dia em pacientes não hospitalizados com aprovação da África do Sul
A autoridade reguladora de produtos de saúde da África do Sul (SAHPRA) aprovou o estudo de Fase 2/3 do RHB-107 (upamostat) administrado por via oral uma vez ao dia para pacientes com COVID-19 sintomática que não precisam de assistência hospitalar O número de unidades de estudo n
Read more →RDHLRedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expande
Read more →RDHLOpaganibe da RedHill Biopharma demonstra redução significativa da fibrose renal
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 9 de setembro de 2021 /PRNewswire/ -- A RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" ou a "Empresa"), uma empresa biofarmacêutica especializada, anunciou hoje os resultados de um novo estudo pré-clínico que demonstra a eficácia d
Read more →RDHLEl opaganib de RedHill Biopharma demuestra una significativa disminución de la fibrosis renal
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 9 de septiembre de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o la "Compañía"), una compañía biofarmacéutica especializada, anunció hoy los resultados de un nuevo estudio preclínico que demuestra la eficac
Read more →RDHLOpaganib von RedHill Biopharma zeigt signifikante Verringerung der Nierenfibrose
- Covid-19- und langzeit Covid-Patienten haben ein erhöhtes Risiko, Nierenschäden zu entwickeln - Opaganib verringerte die Nierenfibrose in einem präklinischen In-vivo-Modell erheblich - Die Nierenfibrose ist ein fortschreitender Prozess, der bei Patienten mit chronischer Niere
Read more →RDHLRedHill Biopharma présente trois nouvelles analyses de données Movantik à PAINWeek 2021
- Deux nouvelles analyses des données de Movantik® (naloxégol) ont évalué la sécurité et l'efficacité de Movantik chez un sous-groupe de patients âgés de 65 ans ou plus. - Les effets de Movantik sur l'amélioration rapide et durable des selles spontanées et des selles complètes e
Read more →RDHLL'opaganib de RedHill Biopharma démontre une diminution significative de la fibrose rénale - Les patients atteints de COVID-19 et de COVID prolongée présentent un risque accru de développer des lésions rénales - L'opaganib diminue...
- Les patients atteints de COVID-19 et de COVID prolongée présentent un risque accru de développer des lésions rénales - L'opaganib diminue considérablement la fibrose rénale dans un modèle préclinique in vivo - La fibrose rénale est un processus progressif qui se produit chez
Read more →RDHLRedHill Biopharma apresenta três novas análises de dados do Movantik na PAINWeek 2021
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 8 de setembro de 2021 /PRNewswire/ -- A RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" ou a "Empresa"), uma empresa biofarmacêutica especializada, anunciou hoje a apresentação na PAINWeek 2021 de três novas análises de dados do est
Read more →RDHLRedHill Biopharma stellt auf der PAINWeek 2021 drei neue Analysen von Movantik-Daten vor
- Zwei neue Analysen der Daten von Movantik® (Naloxegol) bewerteten die Sicherheit und Wirksamkeit von Movantik in einer Untergruppe von Patienten im Alter von ≥ 65 Jahren - Die Analyse der Auswirkungen von Movantik auf die schnelle und anhaltende Verbesserung sowohl des spontan
Read more →RDHLOpaganib, de RedHill Biopharma, demuestra una disminución significativa de la fibrosis renal
- Los pacientes con COVID-19 y COVID prolongado presentan un riesgo superior de desarrollar daño renal - Opaganib ha reducido de forma considerable la fibrosis renal en un modelo preclínico in vivo - La fibrosis renal es un proceso progresivo que ocurre en pacientes con enferme
Read more →RDHLRedHill Biopharma presenta tres nuevos análisis de los datos de Movantik en PAINWeek 2021
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 8 de septiembre de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o la "Empresa"), una empresa biofarmacéutica especializada, anunció hoy la presentación en PAINWeek 2021 de tres nuevos análisis de los datos d
Read more →RDHLRedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation at PAINWeek 2021 of three new analyses of Movantik® (naloxegol) Phase 3 study
Read more →RDHLRedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences
TEL AVIV, Israel and RALEIGH, NC, Sept. 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in September: H.C. Wainwright 23rd
Read more →RDHLRedHill Biopharma informa resultados financeiros e destaques operacionais do segundo trimestre de 2021
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 30 de agosto de 2021 /PRNewswire/ -- A empresa biofarmacêutica especializada RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" ou a "Empresa") divulgou hoje seus resultados financeiros e destaques operacionais do segundo trimestre, qu
Read more →RDHLRedHill Biopharma présente ses résultats financiers et faits saillants opérationnels du deuxième trimestre 2021
- Un chiffre d'affaires trimestriel record de 21,5 millions de dollars pour le deuxième trimestre de 2021, soit une augmentation de 4,5 % par rapport au premier trimestre de 2021, malgré des conditions de marché difficiles ; un solde de trésorerie 1 d'environ 71,5 millions de dol
Read more →RDHLOpaganib de RedHill Biopharma demuestra una fuerte inhibición de la variante Delta de la COVID-19
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 30 de agosto de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o la "Compañía"), una compañía biofarmacéutica especializada, anunció hoy resultados preliminares de un nuevo estudio preclínico que muestra la po
Read more →RDHLRedHill Biopharma informa los resultados financieros y aspectos operacionales destacados del segundo trimestre de 2021
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 30 de agosto de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" o la "Empresa"), una empresa biofarmacéutica especializada, presentó hoy sus resultados financieros y aspectos operacionales destacados del segund
Read more →RDHLOpaganibe da RedHill Biopharma demonstra forte inibição da variante Delta da COVID-19
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 30 de agosto de 2021 /PRNewswire/ -- A empresa biofarmacêutica especializada RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" ou a "Empresa") anunciou hoje os resultados preliminares de um novo estudo pré-clínico que mostra a forte i
Read more →RDHLOpaganib von RedHill Biopharma zeigt starke Hemmung der COVID-19 Delta-Variante
Opaganib zeigte in einem Modell menschlicher Bronchialepithelzellen eine starke Hemmung der COVID-19 Delta-Variante und ergänzt damit frühere Daten, die eine starke Hemmung aller bisher getesteten COVID-19-Varianten belegen Opaganibs einzigartiger, auf den Wirt ausgerichteter, d
Read more →RDHLRedHill Biopharma meldet Finanzergebnisse und operative Highlights für das zweite Quartal 2021
- Erzielung eines Rekordquartalsumsatzes von 21,5 Millionen US-Dollar für Q2/2021, ein Anstieg von 4,5 % gegenüber Q1/2021 trotz schwieriger Marktbedingungen; Kassenbestand 1 von etwa 71,5 Millionen US-Dollar zum 30. Juni 2021 - Rekordverdächtiges vierteljährliches Verschreibung
Read more →RDHLL'opaganib de RedHill Biopharma démontre une forte inhibition du variant Delta de COVID-19 L'opaganib a démontré une forte inhibition du variant Delta de COVID-19 dans un modèle de cellules épithéliales bronchiques humaines, ce qui vient...
L'opaganib a démontré une forte inhibition du variant Delta de COVID-19 dans un modèle de cellules épithéliales bronchiques humaines, ce qui vient s'ajouter aux données antérieures démontrant une inhibition puissante de tous les variants de COVID-19 testés à ce jour L'approche d
Read more →RDHLRedHill Biopharma informa de los resultados financieros del segundo trimestre de 2021
-RedHill Biopharma informa de los resultados financieros del segundo trimestre de 2021 y las operaciones más destacadas - Logró unos ingresos trimestrales récord de 21,5 millones de dólares en el segundo trimestre de 2021, lo que supone un aumento del 4,5% con respecto al primer
Read more →RDHLRedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the second quarter ended June 30, 2021.
Read more →RDHLRedHill Biopharma annonce deux nouveaux brevets américains couvrant l
Les brevets américains pour l'association d'opaganib pour le traitement de la maladie à virus Ebola offrent une protection par brevet jusqu'en 2035 L'étude mondiale de phase 2/3 de l'opaganib, portant sur 475 patients pour le traitement de la forme grave de COVID-19, touche à sa
Read more →RDHLRedHill Biopharma anuncia dos nuevas patentes de los Estados Unidos que cubren el opaganib para el Virus del Ébola y el RHB-104 para la enfermedad de Crohn
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 24 de agosto de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" o la "Compañía"), una empresa biofarmacéutica especializada, anunció hoy que la Oficina de Patentes y Marcas Registradas (USPTO) de los Estados Un
Read more →RDHLRedHill Biopharma anuncia duas novas patentes dos EUA que cobrem o opaganibe para o vírus Ebola e o RHB-104 para a doença de Crohn
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 24 de agosto de 2021 /PRNewswire/ -- ARedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" ou a "Empresa"), uma empresa biofarmacêutica especializada, anunciou hoje que o escritório de patentes e marcas comerciais dos EUA (USPTO) emitiu
Read more →RDHLRedHill Biopharma gibt zwei neue US-Patente für Opaganib für Ebola-Virus und RHB-104 für Crohn bekannt
- US-Patente für Opaganib-Kombination zur Behandlung der Ebola-Viruskrankheit bieten Patentschutz bis 2035 - Opaganibs globale 475-Patienten-Phase-2/3-Studie in schwerer COVID-19 nähert sich Abschluss mit anstehenden Top-Line-Ergebnissen - Opaganib durchläuft auch zwei onkologi
Read more →RDHLRedHill Biopharma anuncia dos nuevas patentes estadounidenses que cubren Opaganib y RHB-104
- RedHill Biopharma anuncia dos nuevas patentes estadounidenses que cubren Opaganib para el virus del ébola y RHB-104 para la enfermedad de Crohn Las patentes de Estados Unidos para la combinación de opaganib para el tratamiento de la enfermedad por el virus del ébola brindan pr
Read more →RDHLRedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn
TEL AVIV, Israel and RALEIGH, N.C., Aug. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued two new patents, one covering
Read more →RDHLRedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021
TEL AVIV, Israel and RALEIGH, NC, Aug. 19, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its second quarter 2021 financial results and operational highlights on T
Read more →RDHLRedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
TEL AVIV, Israel and RALEIGH, NC, July 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca"
Read more →RDHLRedHill Biopharma anuncia el egreso del último paciente del estudio en fase 2/3 del opaganib oral contra la COVID-19
Se completó el seguimiento de los pacientes den estudio global de 475 pacientes en fase 2/3 del opaganib oral contra la COVID-19 severa Se esperan resultados de primera línea en las próximas semanas El opaganib, un nuevo fármaco de acción dual antiviral y antiinflamatoria contr
Read more →RDHLRedHill Biopharma annonce qu
Conclusion de la phase de suivi des patients pour l'étude mondiale de phase 2/3 de 475 patients portant sur l'administration orale de l'opaganib dans le traitement des formes graves de COVID-19 Publication des résultats préliminaires attendue dans les semaines à venir L'étude a
Read more →RDHLRedHill Biopharma anuncia o último paciente para o estudo de Fase 2/3 de opaganibe por via oral para COVID-19
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 21 de julho de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" ou a "Empresa"), uma empresa farmacêutica especializada, líder no desenvolvimento de novas terapias orais para a COVID-19, anunciou hoje que o trata
Read more →RDHLRedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx
TEL-AVIV, Israel and RALEIGH, N.C., July 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that OptumRx, part of the UnitedHealth Group - a leader in healthcare coverage, partnered w
Read more →RDHLRedHill completa el tratamiento del estudio en fase 2/3 de la COVID-19 de opaganib oral
Se ha completado el seguimiento de los 475 pacientes del estudio global de fase 2/3 de opaganib oral para COVID-19 grave Se esperan resultados de primera línea en las próximas semanas Opaganib, una nueva píldora antiviral y antiinflamatoria en investigación contra la COVID-19,
Read more →RDHLRedHill Biopharma Umum Pesakit Terakhir Melengkapkan Kajian Oral Opaganib Fasa 2/3 COVID-19
Susulan untuk pesakit dalam kajian Fasa 2/3 global pada 475 orang pesakit tentang pengambilan opaganib secara oral bagi COVID-19 yang teruk telah lengkap Keputusan barisan teratas dijangka akan diperoleh dalam beberapa minggu akan datang Opaganib ialah pil COVID-19 penyelidikan
Read more →RDHLRedHill Biopharma, 경구용 Opaganib 2/3상 코로나19 연구 완료
-- 중증 코로나19 환자 475명을 대상으로 한 글로벌 2/3상 경구용 Opaganib 연구에서 환자 추적 완료 -- 수 주 이내로 주요 결과 확인 예정 -- 독특한 이중 항바이러스성 및 항염증성 시험용 코로나19 치료제인 Opaganib은 베타 및 감마 변이형을 잠재적으로 억제하는 것으로 나타났으며, 델타 및 델타 플러스를 포함한 새로운 변이형에도 효과가 있을 것으로 기대 이스라엘 텔아비브 및 노스캐롤라이나주 롤리, 2021년 7월 21일 /PRNewswire/ -- 19일, 독특한 코로
Read more →RDHLRedHill Biopharma gibt bekannt, dass der letzte Patient die Phase 2/3-COVID-19-Studie mit oral verabreichtem Opaganib beendet hat
Patientennachsorge der globalen Phase-2/3-Studie an 475 Patienten mit oral verabreichtem Opaganib zur Behandlung von schwerem COVID-19 abgeschlossen Top-Line-Ergebnisse in den kommenden Wochen erwartet Opaganib, eine neuartige, dual-wirkende antivirale und entzündungshemmende C
Read more →RDHLRedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
TEL AVIV, Israel and RALEIGH, NC, July 19, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-u
Read more →RDHLRedHill Biopharma anuncia la presentación de datos positivos del estudio en fase 2 del opaganib administrado por vía oral para combatir la COVID-19
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 23 de junio de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o la "Compañía"), una compañía biofarmacéutica especializada, anunció hoy la presentación de los datos positivos de seguridad y eficacia del estudi
Read more →RDHLRedHill Biopharma präsentiert positive Phase-2-Studiendaten mit oral verabreichtem Opaganib zur Behandlung von COVID-19
Präsentation positiver Sicherheits- und Wirksamkeitsdaten der US-amerikanischen Phase-2-Studie mit Opaganib, ein führender neuartiger, oraler, dualer Wirkstoffkandidaten für die Behandlung von mittelschwerer bis schwerer COVID-19, auf dem World Microbe Forum Opaganib steht in Ve
Read more →RDHLRedHill Biopharma anuncia apresentação de dados positivos de Fase 2 do Opaganib administrado por via oral em COVID-19
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 23 de junho de 2021 /PRNewswire/ -- A empresa biofarmacêutica especializada RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" ou a "Empresa") anunciou hoje a apresentação dos dados positivos de segurança e eficácia de Fase 2 do Opagan
Read more →RDHLRedHill Biopharma annonce la présentation de données positives de phase 2 sur l
Présentation, lors du World Microbe Forum, de données positives de phase 2 aux États-Unis sur l'innocuité et l'efficacité de l'opaganib, un nouveau médicament candidat oral à double mécanisme pour le traitement de la COVID-19 modérée à sévère. L'opaganib a été associé une réduct
Read more →RDHLRedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC
Read more →RDHLRedHill Biopharma to Present at the BIO Digital International Convention
TEL AVIV, Israel and RALEIGH, N.C., June 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill's Chief Corporate & Business Development Officer, will present a
Read more →RDHLRedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
TEL AVIV, Israel and RALEIGH, NC, June 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study
Read more →RDHLRedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights
TEL AVIV, Israel and RALEIGH, N.C., May 27, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the first quarter ended March 31, 2021.
Read more →RDHLRedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19
TEL AVIV, Israel and RALEIGH, NC, May 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering
Read more →RDHLRedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021
TEL AVIV, Israel and RALEIGH, N.C., May 24, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation at Digestive Disease Week (DDW) 2021 of two new analyses of Movantik® Phase 3 s
Read more →RDHLRedHill Biopharma Presents a New Travelers
TEL AVIV, Israel and RALEIGH, N.C., May 21, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation (poster number: Fr244) at Digestive Disease Week 2021 of a new Travelers' Diarr
Read more →RDHLRedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021
TEL AVIV, Israel and RALEIGH, N.C., May 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2021 financial results and operational highlights on T
Read more →RDHLRedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals
TEL AVIV, Israel and RALEIGH, N.C., March 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AztraZeneca AB and AstraZenca Pharmaceuticals LP ("AZ") and N
Read more →RDHLRedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland
TEL AVIV, Israel and RALEIGH, N.C., March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib[1] treatment on an outpatient basis und
Read more →RDHLRedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
TEL AVIV, Israel and RALEIGH, N.C., March 18, 2021 /PRNewswire/ -- Full year 2020 net revenues of approximately $64 million, with gross profit of approximately $27.5 million Solid cash balance of approximately $100 million as of March 4, 2021 Planned commercial operational bre
Read more →RDHLRedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021
TEL AVIV, Israel and RALEIGH, NC, March 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2020 financial results and operational
Read more →RDHLRedHill to Present at Upcoming Conferences in March
TEL AVIV, Israel and RALEIGH, NC, March 5, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March: Sachs Spring Li
Read more →RDHLRedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C., March 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 4,375,000 American
Read more →RDHLRedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary Shares
TEL AVIV, Israel and RALEIGH, NC, March 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announc
Read more →RDHLRedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C., March 1, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under wh
Read more →RDHLRedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plans to expand the Company's global Phase 2/3 study of opaganib[1] in patients with seve
Read more →RDHLRedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204
TEL AVIV, Israel and RALEIGH, N.C., Feb. 18, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreements with Cosmo Pharmaceuticals NV (SIX: COPN) ("Cosmo") to manufacture two key produ
Read more →RDHLRedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient was dosed in its U.S. Phase 2/3 study of orally-administered RHB-107
Read more →RDHLRedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences
TEL AVIV, Israel and RALEIGH, N.C., Feb. 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in February: SVB Leerink 10th Ann
Read more →RDHLRedHill Biopharma anuncia valoración positiva de la futilidad del DSMB para el estudio de fase 2/3 de opaganib para la COVID-19
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 2 de febrero de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o la "Compañía"), una compañía especializada en la biofarmacéutica, anunció hoy que el Comité de Monitoreo de Datos y Seguridad (DSMB) independien
Read more →RDHLRedHill Biopharma anuncia avaliação positiva de futilidade pelo DSMB para estudo de Fase 2/3 do opanagibe para a COVID-19
TEL AVIV, Israel e RALEIGH, N.C, 2 de fevereiro de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" ou a "Empresa"), empresa biofarmacêutica especializada, anunciou hoje que o Conselho de Monitoramento de Dados e Segurança (DSMB) para o estudo global de Fase
Read more →RDHLRedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of
Read more →RDHLRedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
TEL AVIV, Israel and RALEIGH, N.C., Jan. 28, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced a manufacturing agreement with Cosmo Pharmaceuticals NV (SIX: COPN) ("Cosmo") to further ex
Read more →RDHLRedHill Biopharma Announces Closing of $25 Million Bought Deal Offering
TEL AVIV, Israel and RALEIGH, N.C., Jan. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten offering of 3,188,776 American Deposit
Read more →RDHLRedHill-Partner Cosmo Pharmaceuticals schließt erfolgreich Phase-2-Studie mit Rifamycin SV-MMX 600 mg für IBS-D ab
TEL AVIV, Israel, und RALEIGH, N.C., 13. Januar 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL), (FRA: 2RH) („RedHill" oder „das Unternehmen"), ein spezialisiertes biopharmazeutisches Unternehmen, gab heute bekannt, dass sein Partnerunternehmen Cosmo Pharmaceuticals (S
Read more →RDHLCosmo Pharmaceuticals, partenaire de RedHill, a achevé avec succès son étude de phase 2 sur la rifamycine SV-MMX 600 mg dans le SII-D
TEL AVIV, Israël et RALEIGH, Caroline du Nord, 13 janvier 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq : RDHL) (« RedHill » ou « la Société »), une société biopharmaceutique spécialisée, a rapporté aujourd'hui que son partenaire, Cosmo Pharmaceuticals (SIX : COPN) (« Cosmo
Read more →RDHLRedHill Biopharma Increases Previously Announced Bought Deal to $25 Million
TEL AVIV, Israel and RALEIGH, N.C., Jan. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously annou
Read more →RDHLEl socio de RedHill, Cosmo Pharmaceuticals, completa con éxito el estudio de fase 2
- El studio evaluado rifamicina SV-MMX 600mg en IBS-D TEL AVIV, Israel y RALEIGH, N.C., 12 de enero de 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o "la Compañía"), una empresa biofarmacéutica especializada, informó hoy que su socio, Cosmo Pharmaceutica
Read more →RDHLRedHill Biopharma Announces $10 Million Bought Deal Offering
TEL AVIV, Israel and RALEIGH, N.C., Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under wh
Read more →RDHLRedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today reported that its partner, Cosmo...
TEL AVIV, Israel and RALEIGH, N.C,, Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ("Cosmo"), announced that it had success
Read more →RDHLRedHill Biopharma anuncia datos positivos de primera línea acerca de la seguridad y eficacia del estudio de fase 2 con Opaganib para tratar la COVID-19
Los datos preliminares del estudio sin poder estadístico en fase 2 de los Estados Unidos de 40 pacientes hospitalizados muestran que el opaganib administrado por vía oral fue seguro, sin diferencias de seguridad material entre el opaganib y los brazos de control Las tendencias c
Read more →RDHLRedHill Biopharma anuncia dados positivos de primeira linha de segurança e eficácia do estudo de Fase 2 de opaganbe para COVID-19
Dados preliminares do estudo de Fase 2 dos EUA, sem poder estatístico realizado com 40 participantes hospitalizados mostram que o opaganibe administrado por via oral é seguro, sem diferenças materiais de segurança entre o opaganibe e os grupos de controle Tendências consistentes
Read more →RDHLRedHill Biopharma gibt positive Topline-Sicherheits- und Wirksamkeitsdaten der Phase-II-COVID-19-Studie mit Opaganib bekannt
Vorläufige Daten der U.S. Phase-II-Studie „ohne statistische Signifikanz" an 40 Patienten im Krankenhaus zeigen, dass oral verabreichtes Opaganib sicher war, ohne wesentliche Unterschiede zwischen Opaganib und Kontrollgruppen Konsistente Tendenzen zeigen eine größere Verbesserun
Read more →RDHLRedHill Biopharma anuncia datos positivos de seguridad y eficacia del estudio de COVID-19 de fase 2 de Opaganib
Los datos preliminares del estudio en Fase 2 de Estados Unidos de 40 pacientes hospitalizados muestran que opaganib administrado por vía oral era seguro, sin diferencias materiales de seguridad entre opaganib y los brazos de control Las tendencias consistentes demuestran una may
Read more →RDHLRedHill Biopharma annonce les résultats positifs de la phase 2 de l
Les données préliminaires de la phase 2 de l'étude américaine portant sur 40 patients hospitalisés montrent que l'opaganib administré par voie orale était sûr, sans différence de sécurité matérielle entre l'opaganib et les groupes témoins Des tendances cohérentes démontrent une
Read more →RDHLRedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Dec. 31, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that preliminary top-line data from its U.S. Phase 2 study with orally-administered opagani
Read more →RDHLEstudo de fase 2/3 para COVID-19 da RedHill com opaganibe passa pela segunda recomendação unânime do DSMB para continuar
TEL AVIV, Israel e RALEIGH, N.C., 24 de dezembro de 2020 /PRNewswire/ -- A RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" ou a "empresa"), uma empresa biofarmacêutica especializada, anunciou hoje que o estudo global de Fase 2/3 com opaganibe (Yeliva®, ABC294640)[1] administrado
Read more →RDHLEstudio de fase 2/3 con opaganib para tratar la COVID-19 de RedHill recibe recomendación unánime del DSMB para continuar
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 24 de diciembre de 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o la "Compañía"), una compañía especializada en biofarmacéutica, anunció hoy que el estudio global de fase 2/3 con administración oral de opaga
Read more →RDHLL'étude COVID-19 phase 2/3 de RedHill sur l'opaganib passe le deuxième DSMB avec une recommandation unanime de poursuivre Le DSMB indépendant recommande à l'unanimité la poursuite de l'étude mondiale de phase 2/3 sur l'opaganib administré par voie orale dans le cadre de...
Le DSMB indépendant recommande à l'unanimité la poursuite de l'étude mondiale de phase 2/3 sur l'opaganib administré par voie orale dans le cadre de la COVID-19 grave, sur la base de l'examen des données de sécurité non masquées provenant de 155 patients traités Les données de l
Read more →RDHLZweites DSMB Meeting gibt einstimmige Empfehlung, RedHills Phase-2/3-Studie mit Opaganib zur Behandlung von COVID-19 fortzusetzen
- Basierend auf der Überprüfung nicht blinder Sicherheitsdaten von 155 behandelten Patienten, empfiehlt das „Data Safety and Monitoring Board" (DSMB) die globale Phase-2/3-Studie mit oral verabreichtem Opaganib zur Behandlung von schwerem COVID-19 fortzusetzen - Top-Line-Daten a
Read more →RDHLEl estudio de COVID-19 de fase 2/3 de RedHill de Opaganib aprueba un segundo DSMB
- El estudio de COVID-19 de fase 2/3 de RedHill de Opaganib aprueba un segundo DSMB con recomendación unánime para continuar El DSMB independiente recomienda unánimemente la continuación del estudio de fase 2/3 global de opaganib administrado oralmente en COVID-19 grave basado e
Read more →RDHLRedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced that the global Phase 2/3...
TEL AVIV, Israel and RALEIGH, N.C., Dec. 22, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva®, ABC294640)[1] i
Read more →RDHLOpaganib, el fármaco de RedHill para la COVID-19 que se encuentra en fase 2/3 de estudio, reduce la coagulación de la sangre relacionada con el SDRA en un modelo preclínico
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 17 de diciembre de 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o la "Compañía"), una compañía biofarmacéutica especializada, anunció hoy resultados preliminares prometedores de un estudio preclínico en el q
Read more →RDHLDer RedHill-Phase-II/III-Kandidat Opaganib reduziert ARDS-bedingte Blutgerinnung im präklinischen Modell bei COVID-19-Patienten
Eine durch das akute Atemnotsyndrom (ARDS) induzierte Thrombose (Blutgerinnung) kann bei bis zu einem Drittel der auf der Intensivstation behandelten COVID-19-Patienten auftreten und ist eine der Todesursachen In einem präklinischen ARDS-Modell zeigte sich bei der Behandlung mit
Read more →RDHLL'opaganib, candidat thérapeutique pour le traitement du COVID-19 dans l'étude de phase 2/3 de RedHill, diminue le système de coagulation sanguine liée au SDRA dans des modèles précliniques La thrombose (coagulation sanguine) induite par le syndrome de détresse respiratoire aiguë (SDRA) peut se produire chez un tiers des patients...
La thrombose (coagulation sanguine) induite par le syndrome de détresse respiratoire aiguë (SDRA) peut se produire chez un tiers des patients COVID-19 nécessitant une admission en soins intensifs et constitue une cause de mortalité L'opaganib a démontré une réduction de la throm
Read more →RDHLOpaganibe, candidato da RedHill no estudo de Fase 2/3 da COVID-19, reduz coagulação sanguínea relacionada induzida pela SDRA no modelo pré-clínico
TEL AVIV, Israel e RALEIGH, Carolina do Norte, 17 de dezembro de 2020 /PRNewswire/ -- A RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" ou a "Empresa"), empresa biofarmacêutica especializada, anunciou hoje os resultados preliminares promissores de um estudo pré-clínico no qual o
Read more →RDHLEl opaganib, candidato de RedHill para COVID-19, reduce los coágulos sanguíneos relativos al ARDS
- El opaganib, candidato de RedHill para COVID-19 en fase 2/3, reduce los coágulos sanguíneos relativos al ARDS en el modelo preclínico La trombosis (coágulo sanguíneo) inducida por el síndrome del estrés respiratorio agudo (ARDS) puede causar que hasta un tercio de pacientes co
Read more →RDHLRedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced promising preliminary...
TEL AVIV, Israel and RALEIGH, N.C., Dec. 15, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study within which opaganib, a novel, oral
Read more →RDHLRedHill Biopharma Added to NASDAQ Biotechnology Index
TEL AVIV, Israel and RALEIGH, N.C., Dec. 14, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI).
Read more →RDHLRedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans
TEL AVIV, Israel and RALEIGH, N.C., Dec. 7, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has increased unrestricted national and regional commercial coverage for Talicia® (o
Read more →RDHLRedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19
TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of op
Read more →RDHLRedHill anuncia recomendación unánime del DSMB para continuar el estudio de fase 2/3 con opaganib para tratar la COVID-19
TEL AVIV, Israel y RALEIGH, Carolina del Norte, 23 de noviembre de 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o la "Compañía"), una compañía con especialidad en biofarmacéutica, anunció hoy que estudio global fase 2/3 con opaganib (Yeliva®, ABC294640)[1
Read more →RDHLRedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferences in December: Eve
Read more →RDHLRedHill anuncia recomendação unânime do DSMB para continuar o estudo de fase 2/3 com opaganibe da COVID-19
TEL AVIV, Israel e RALEIGH, N.C., 23 de novembro de 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" ou a "empresa"), empresa biofarmacêutica especializada, anunciou hoje que o estudo global de Fase 2/3 com opaganibe (Yeliva®, ABC294640) [1] em pacientes hosp
Read more →RDHLRedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
TEL AVIV, Israel and RALEIGH, N.C., Nov. 20, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today announced that it has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a
Read more →RDHLRedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Nov. 19, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitali
Read more →RDHLRedHill Biopharma hält Präsentation auf Deutschem Eigenkapitalforum 2020
RedHill Biopharma will present at the German Equity Forum 2020, showcasing its business overview and pipeline. Guy Goldberg, the Chief Business Officer, will lead the presentation and conduct one-on-one investor meetings. The event is significant as it is one of Europe's largest investor gatherings, emphasizing RedHill's commitment to engaging with the investment community.
Read more →RDHLRedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks
TEL AVIV, Israel and RALEIGH, NC, Nov. 16, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitalized wi
Read more →RDHLRedHill Biopharma to Present at German Equity Forum 2020
RedHill Biopharma announced that its Chief Business Officer, Guy Goldberg, will present at the German Equity Forum 2020 on November 17. The event is one of Europe's largest investor gatherings, where RedHill will provide a corporate overview and hold one-on-one meetings with investors. The presentation will be available for replay on the company's website for 30 days.
Read more →RDHLRedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
RedHill Biopharma reported a strong Q3 2020 with net revenues of approximately $21 million, driven by a 300% increase in Talicia prescriptions. The company also noted a reversal in Movantik prescription trends and significant progress in its COVID-19 studies with opaganib. However, the operating loss and net loss increased compared to the previous quarter, reflecting higher expenses.
Read more →RDHLRedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020
RedHill Biopharma will announce its third-quarter 2020 financial results on November 12, 2020. The company will host a conference call and webcast at 8:30 a.m. EST to discuss key highlights. RedHill focuses on gastrointestinal and infectious diseases, with several ongoing clinical programs.
Read more →RDHLRedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
RedHill Biopharma has received a Notice of Allowance for a patent covering the combination of its investigational drugs, opaganib and RHB-107, for treating solid tumor cancers. This patent is expected to extend intellectual property protection until 2036. Recent pre-clinical studies demonstrated significant antitumor effects, prompting RedHill to consider adding a new cohort to its ongoing Phase 2a study, pending FDA discussions.
Read more →RDHLRedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
RedHill Biopharma presented new data at the ACG 2020 meeting, highlighting Talicia's effectiveness as a first-line treatment for H. pylori eradication. The data demonstrated that Talicia's efficacy is unaffected by patient BMI, contrasting with declining success rates of traditional clarithromycin-based therapies. The findings emphasize the importance of addressing antibiotic resistance in H. pylori treatment.
Read more →RDHLRedHill Biopharma объявляет партнеров для расширения производства Opaganib как потенциального средства терапии для лечения COVID-19
RedHill Biopharma has announced collaborations with European and Canadian suppliers to enhance the production of opaganib, a potential treatment for COVID-19. This partnership aims to increase manufacturing capabilities as the drug progresses through Phase 2/3 clinical trials. The company is optimistic about the drug's potential in severe COVID-19 cases, with ongoing studies in the US.
Read more →RDHLRedHill Biopharma annonce des partenariats visant à augmenter la fabrication de l'opaganib, candidat thérapeutique pour le traitement du COVID-19
RedHill Biopharma has announced partnerships with European and Canadian manufacturers to scale up production of opaganib, a therapeutic candidate for COVID-19. The company is advancing its Phase 2/3 study for severe pneumonia related to COVID-19, with recruitment nearing completion in the U.S. and ongoing globally. Opaganib has demonstrated significant antiviral activity against SARS-CoV-2, and RedHill is discussing potential funding with U.S. agencies to expedite its development.
Read more →RDHLRedHill Biopharma 宣佈合作夥伴關係，以擴大 COVID-19 治療候選藥物 Opaganib 的生產
RedHill Biopharma has announced a collaboration with two companies to enhance the production of opaganib, a treatment for COVID-19. The Phase 2/3 clinical trials are advancing quickly, with expectations for completion soon. The collaboration aims to support the urgent application for emergency use authorization in the U.S.
Read more →RDHLRedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming weeks Orphan Drug Designation, along with RHB-204’s FDA QIDP priority designation, will extend U.S. potential market exclusivity to a total of 12 years TEL AVIV, Israel and RALEIGH, N.C.,
Read more →RDHLRedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib
Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthens manufacturing capabilities and capacity, in preparation for potential emergency use applications Enrollment in the global Phase 2/3 COVID-19 study with opaga
Read more →RDHLRedHill Biopharma Adds Israel Rights to Movantik From AstraZeneca
RedHill obtains Israel rights to Movantik® from AstraZeneca, giving RedHill global rights, excluding Europe and Canada Movantik approved for opioid-induced constipation in Israel under the brand name Moventig® RedHill to evaluate partnering opportunities for commercialization o
Read more →RDHLRedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review
Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19 The U.S. Phase 2 study is 75% enrolled with data expected later this quarter In parallel, enrollment
Read more →RDHLRedHill Biopharma to Present at BIO Investor and BIO-Europe 2020 Virtual Conferences
TEL AVIV, Israel and RALEIGH, N.C., Oct. 06, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in October: BIO Investor For
Read more →RDHLSECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2020 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registr
Read more →RDHLRedHill to Present at the Morgan Stanley Annual Global Healthcare Conference and Additional September Events
TEL AVIV, Israel and RALEIGH, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that RedHill’s Chief Executive Officer, Dror Ben-Asher, will present at the Morgan Sta
Read more →RDHLRedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study Opaganib is uniquely positioned as an orally-administered pot
Read more →RDHLRedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania
A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia, and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with dual anti-inflammatory and anti-
Read more →RDHLRedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled and enrollment is planned to be completed in the coming weeks The global Phase 2/3 COVID
Read more →RDHLRedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. (SIX: COP
Read more →RDHLRedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights
Q2/2020 net revenues of approximately $21 million, up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase of approximately 1,900% and 1,200%, respectively Completed acquisition of Movantik® from AstraZeneca and secured exclusive control over U.S. commercializat
Read more →RDHLRedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico
The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites The global Phase 2/3 study has been approved in Mexico, the UK and Russia and is also under review in Italy, Brazil and additional countries Enrollment in
Read more →RDHLRedHill Biopharma to Host Second Quarter Financial Results and Business Highlights Conference Call and Webcast on August 13, 2020
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its second quarter 2020 financial results and business highlights o
Read more →RDHLRedHill Biopharma to Participate in Upcoming BTIG and Intellisight Conferences
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will participate in the following virtual conferences in August: BTIG Virtual
Read more →RDHLRedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik
RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019 RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik® with a new royalty-bearing agreement, under which RedHill wil
Read more →RDHLRedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
RHB-204 is a potential first-line oral treatment for pulmonary nontuberculous mycobacteria (NTM) infections, a rare disease with no FDA-approved first-line therapy The pivotal Phase 3 study aims to enroll 125 patients at 50 clinical sites across the U.S. RHB-204 was granted QID
Read more →RDHLRedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy, Brazil and Mexico Enrollment in a parallel U.S. Phase 2 study in patients with severe COVID-19
Read more →RDHLRedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda®) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), meeting the study’s primary endpo
Read more →RDHLRedHill Biopharma Increases Patient Access to Talicia with EnvisionRx Formularies
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to clarithromycin-based therapies Talicia® is targeting an estimated two million U.S. patients trea
Read more →RDHLRedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
Phase 2/3 study process initiated in Brazil and Mexico The global Phase 2/3 study with opaganib in patients with severe COVID-19 has already been approved in the UK and Russia Enrollment planned to be initiated this month - 270 subjects to be enrolled in up to 40 clinical sites
Read more →RDHLRedHill Biopharma Seeks SEC Review of Suspicious Trading Activity
TEL-AVIV, Israel and RALEIGH, N.C., July 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, announced today it is seeking regulatory review by the Securities and Exchange Commission (“SEC”), and
Read more →RDHLRedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia
Clinical Trial Application approved in Russia for the Phase 2/3 study with opaganib in severe COVID-19 patients following recent approval in the UK and similar submission in Italy The Phase 2/3 study aims to enroll 270 subjects in up to 40 clinical sites; enrollment planned to b
Read more →RDHLRedHill Biopharma to Present at the Sachs Novel Coronavirus Investment Forum
TEL-AVIV, Israel and RALEIGH, N.C., July 01, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present the Company’s on
Read more →RDHLRedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK
The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across the UK, Italy, Russia and additional countries In parallel, a U.S. study with opaganib in up t
Read more →RDHLRedHill Biopharma to Present at Virtual Life Sciences Investor Forum on June 25
TEL-AVIV, Israel and RALEIGH, N.C., June 22, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Guy Goldberg, RedHill's Chief Business Officer, will present a corporate overview
Read more →RDHLRedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study with opaganib in 270 severe COVID-19 patients is planned to be conducted in up to 40 clinical sites across Russia, Italy, the UK and additional countries In parallel, a clinical
Read more →RDHLRedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be conducted in Russia and additional European and other countries In parallel, a Phase 2a clinical study of opaganib for
Read more →RDHLRedHill Biopharma to Provide Update on its COVID-19 and other Development Programs at MedInvest Virtual Infectious Diseases and Immunology Conference
TEL-AVIV, Israel and RALEIGH, N.C., June 08, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Gilead Raday, RedHill’s Chief Operating Officer, will present the Company’s de
Read more →RDHLRedHill Biopharma to Present at BIO Digital
TEL-AVIV, Israel and RALEIGH, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill’s Senior Vice President Business Development and Licensing,
Read more →RDHLRedHill Biopharma to Present at Jefferies Virtual Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate ove
Read more →RDHLRedHill Biopharma Provides Q1/2020 Financial Results and Recent Highlights Including Initial Movantik Revenues
Completed acquisition of Movantik® from AstraZeneca on April 1, 2020, and initiated U.S. promotion with net revenues of $7.3 million in April Launched commercial sales of Talicia® in the U.S. in March 2020; Talicia® added to Express Scripts and Prime Therapeutics formularies as
Read more →RDHLRedHill Biopharma to Host First Quarter Financial Results Conference Call on May 27, 2020
TEL-AVIV, Israel and RALEIGH, N.C., May 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its first quarter 2020 financial results on Wednesday, May 27, 2020.
Read more →RDHLRedHill Biopharma to Present at the UBS Virtual Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate ove
Read more →RDHLRedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. All six analyzed moderate-to-severe COVID-19 patients treated with opaganib under compassionate use in Israel were weaned from oxygen an
Read more →RDHLRedHill Biopharma Announces Publication of Talicia Pivotal Phase 3 Study Results in Annals of Internal Medicine
Talicia® is approved by the U.S. FDA and promoted by RedHill’s U.S. sales force Abstract discussing Talicia pharmacokinetics and exposure-response presented as ePoster at Digestive Disease Week® (DDW) 2020 TEL-AVIV, Israel and RALEIGH, N.C., May 05, 2020 (GLOBE NEWSWIRE) -- Red
Read more →RDHLRedHill Biopharma Strengthens Coverage for Talicia with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies H. pylori bacterial infection is a Group 1 carcinogen and the strongest
Read more →RDHLRedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
TEL-AVIV, Israel and RALEIGH, N.C., April 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into an agreement with the National Institute of Allergy and Infec
Read more →RDHLRedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel
Objective improvement in first two patients treated with opaganib in Israel who have demonstrated measurable clinical improvement within days of treatment initiation, including decreased supplemental oxygen requirements, decreased C-reactive protein (CRP) levels and increased lym
Read more →RDHLRedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use
Compassionate use approved by Israeli Ministry of Health; Additional patients expected to be treated in the coming days Discussions ongoing in the U.S. and other countries TEL-AVIV, Israel and RALEIGH, N.C., April 06, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDH
Read more →RDHLRedHill Biopharma Announces Approval of Compassionate Use of Opaganib for COVID-19 in Italy
Authorization of compassionate use granted by the Italian authorities, aided by RedHill’s strategic partner, Cosmo Pharmaceuticals N.V. (SIX: COPN) Approximately 160 patients with life-threatening clinical manifestations planned to be treated in three major hospitals in northern
Read more →RDHLRedHill Biopharma Completes Acquisition of Movantik from AstraZeneca
RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and Aemcolo® Movantik® generated U.S. net sales of $96 million in 2019 TEL-AVIV, Israel and RALEIGH, N.C., Ap
Read more →RDHLRedHill Biopharma Provides Business Update
TEL-AVIV, Israel and RALEIGH, N.C., March 25, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today provided a business update on proactive measures being take
Read more →RDHLRedHill Biopharma to Present at Virtual Life Sciences Investor Forum on March 26
TEL-AVIV, Israel and RALEIGH, N.C., March 23, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that Guy Goldberg, RedHill's Chief Business Offic
Read more →RDHLRedHill Biopharma Announces Preferred Position for Talicia on Express Scripts National Preferred Formulary Effective March 13, 2020
RedHill recently launched Talicia® in the U.S., calling on gastroenterologists, primary care physicians and other healthcare providers Talicia® is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to addr
Read more →RDHLRedHill Biopharma Provides Update on Opaganib (Yeliva )
Phase 2 study evaluating RedHill’s proprietary NCE1 opaganib (Yeliva®, ABC294640) in prostate cancer initiated at Medical University of South Carolina, supported by an NCI grant Recruitment initiated in second arm of Phase 1/2a study evaluating opaganib in combination with hydro
Read more →RDHLRedHill Biopharma to Present at the Barclays Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., March 10, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executiv
Read more →RDHLRedHill Biopharma Announces U.S. Commercial Launch of Talicia for H. pylori Infection
Talicia® is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to address the high and growing H. pylori resistance to clarithromycin Talicia® is targeting an estimated two million U.S. patients treated an
Read more →RDHLRedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights
Talicia® approved by the FDA for the treatment of H. pylori infection in adults; U.S. launch with RedHill’s sales force expected by mid-March 2020 Acquisition of global rights to Movantik® (naloxegol) for the treatment of opioid-induced constipation (OIC) in adults from AstraZen
Read more →RDHLRedHill Biopharma to Host Full-Year 2019 Financial Results Conference Call on March 4, 2020
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gas
Read more →RDHLRedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners
RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia® this quarter and the ongoing promotion of Aemcolo® RedHill will receive an additional $50 million to fund the acquisition of rights to Movantik® from A
Read more →RDHLRedHill Biopharma Acquires Rights to Movantik from AstraZeneca
RedHill to promote Movantik® in the U.S. upon closing Movantik® generated U.S. net sales of $96 million in 2019 Acquisition financing to be provided by HealthCare Royalty Partners (HCR) as part of the $115 million non-dilutive financing TEL-AVIV, Israel and RALEIGH, N.C., Feb.
Read more →RDHLRedHill Biopharma to Present at the 9th Annual SVB Leerink Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 18, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gas
Read more →RDHLRedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia Launch
RedHill is on track to launch Talicia® in the U.S. in the first quarter of 2020 for the treatment of H. pylori infection in adults RedHill to sponsor H. pylori medical education event at the Pri-Med South Conference scheduled for February 6-9, 2020 RedHill to sponsor the No Sto
Read more →RDHLRedHill Biopharma to Focus Commercial Efforts on Talicia and Aemcolo ; Discontinuing Promotion of Legacy Products
TEL-AVIV, Israel and RALEIGH, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary dr
Read more →RDHLRedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106
TEL-AVIV, Israel and RALEIGH, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary dr
Read more →RDHLRedHill Biopharma Initiates U.S. Promotion of Aemcolo for Travelers’ Diarrhea
Aemcolo® (rifamycin) is a non-systemic antibiotic delivered directly to the site of non-invasive E. coli infection in the lower intestine Aemcolo® is approved by the FDA for the treatment of travelers’ diarrhea, and is covered by a robust U.S. patent portfolio which, together wi
Read more →RDHLRedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights
U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to commercialize Aemcolo® in the U.S. for travelers’ diarrhea Accelerating exp
Read more →RDHLRedHill Biopharma to Host Third Quarter 2019 Financial Results Conference Call on November 19, 2019
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietar
Read more →RDHLRedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietar
Read more →RDHLRedHill Biopharma Announces FDA Approval of Talicia for Treatment of H. pylori in Adults
RedHill plans to launch Talicia®1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection annually Talicia® is the first and only FDA approved rifabutin-based H. pylori th
Read more →RDHLRedHill Biopharma to Present at the BIO-Europe 2019 Conference
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical l
Read more →RDHLRedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical l
Read more →RDHLRedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical l
Read more →RDHLRedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 16, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical l
Read more →RDHLRedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical l
Read more →RDHLRedHill Biopharma Provides H2/2019 R&D Update
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical
Read more →RDHLRedHill Biopharma to Present at Upcoming Investor Conferences in September
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 27, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical l
Read more →RDHLRedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical l
Read more →RDHLRedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights
Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori for priority review and assignment of a target PDUFA action date of November 2, 2019 Preparations ongoing for the potential U.S. commercial launch of Talicia
Read more →RDHLRedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019
TEL-AVIV, Israel and RALEIGH, N.C., July 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical l
Read more →RDHLRedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia
U.S. FDA accepts NDA for priority review PDUFA date set for November 2, 2019 H. pylori infection affects approximately 35% of the U.S. population and is the strongest risk factor for the development of gastric cancer and a major risk factor for peptic ulcer disease and MALT lym
Read more →RDHLRedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
The new patent expands the robust patent portfolio covering RHB-104 and RHB-204 RedHill plans to initiate a pivotal Phase 3 study with RHB-204 for the treatment of pulmonary nontuberculous mycobacteria (NTM) infections in the second half of 2019 RedHill plans to meet with the F
Read more →RDHLRedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer
TEL-AVIV, Israel and RALEIGH, N.C., May 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appoi
Read more →RDHLRedHill Biopharma to Present at 2019 BIO International Convention
TEL-AVIV, Israel and RALEIGH, N.C., May 23, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that
Read more →RDHLRedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia Launch
Rob Jackson joins as Vice President of Marketing Robert J. Gilkin, Jr. joins as Vice President of Market Access Steven Thomasian to join as Vice President of Supply Chain TEL-AVIV, Israel and RALEIGH, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL)
Read more →RDHLRedHill Biopharma Reports First Quarter 2019 Financial Results and Operational Highlights
Key Highlights and Upcoming Milestones: NDA submitted to the FDA for Talicia® for H. pylori infection, with potential U.S. commercial launch in Q4/2019, assuming FDA approval FDA meeting planned for H2/2019 to discuss design of confirmatory Phase 3 study and path to potential a
Read more →RDHLRedHill Biopharma Submits New Drug Application for Talicia for H. pylori Infection
The NDA follows a recent positive pre-NDA meeting with the FDA The NDA for Talicia® is eligible for six-month priority review Talicia® is eligible for a total of eight years of U.S. market exclusivity, in addition to patent protection until at least 2034 RedHill continues to s
Read more →RDHLRedHill Biopharma to Host First Quarter 2019 Financial Results Conference Call on May 7, 2019
TEL-AVIV, Israel and RALEIGH, N.C., April 30, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that it
Read more →RDHLRedHill Biopharma to Present at Three Conferences in April
TEL-AVIV, Israel and RALEIGH, N.C., April 04, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that th
Read more →RDHLRedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference
TEL-AVIV, Israel and RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced th
Read more →RDHLRedHill Biopharma to Present at the 31st Annual ROTH Conference
TEL-AVIV, Israel and RALEIGH, N.C., March 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced th
Read more →RDHLRedHill Biopharma Announces New European and Japanese Patents for Talicia
The European and Japanese patent applications have been accepted and, once granted, are expected to be valid until 2034 U.S. NDA for Talicia® on track for potential submission in H1/2019 and U.S. commercial launch in Q4/2019 Talicia® was granted QIDP designation, including elig
Read more →RDHLRedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today reported its
Read more →RDHLRedHill Biopharma to Host Full-Year 2018 Financial Results Conference Call on February 26, 2019
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, to
Read more →RDHLRedHill Biopharma Strengthens Management Team with Appointment of Rick D. Scruggs as Chief Operating Officer, U.S. Operations
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 20, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) disease
Read more →RDHLRedHill Biopharma to Present at the 8th Annual SVB Leerink Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) disease
Read more →RDHLRedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA for H. pylori Infection
Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034 NDA submission is expected in H1/2019, with eligibility for 6-month priority review; Subject to FDA approval, U.S. commercial launch with RedHill’s existing sales force is plan
Read more →RDHLRedHill Biopharma Announces Closing of $20 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, toda
Read more →RDHLRedHill Biopharma Announces Pricing of $20 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, toda
Read more →RDHLRedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, to
Read more →RDHLRedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA for H. pylori Infection
The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance (p<0.0001) High resistance to standard-of-care antibiotics observed in the ERADICATE Hp2 study is consistent wit
Read more →RDHLRedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, to
Read more →RDHLRedHill Biopharma Announces Presentation on YELIVA (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and
Read more →RDHLRedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights
Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA filing in early 2019 Positive top-line results from the Phase III study with RHB-104 for Crohn’s disease - the study suc
Read more →RDHLRedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, to
Read more →RDHLRedHill Biopharma to Host Analyst and Investor Webcast on TALICIA for H. pylori infection on October 30, 2018
Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018 H. pylori bacterial infection affects over 50% of the adult population worldwide and 30-40% of the U.S. population TEL-AVIV, Israel and RALEIGH, N.C., Oct. 29, 2018 (GLOBE NEWSWIR
Read more →RDHLRedHill Biopharma to Present at the BIO-Europe 2018 Conference
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 25, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, to
Read more →RDHLRedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA for H. pylori Infection
RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDT Final patient assessed for primary endpoint, with top-line results expected before year-end 2018 If successful, RedHill plans to file a U.S. NDA
Read more →RDHLRedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018
The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of clinical remission at week 26 (p=0.007) and key secondary and other efficacy endpoints of clinical response at week 26 (p=0.016), early clinical remission at week 16
Read more →RDHLRedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 10, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, to
Read more →RDHLRedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, t
Read more →RDHLRedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA for IBS-D
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders In light of the clarity provided by the FDA regarding the clinical and regulator
Read more →RDHLRedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA for Cholangiocarcinoma
The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patien
Read more →RDHLRedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA for H. pylori Infection
Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA® are expected before year’s end The ERADICATE Hp2 study enrolled 455 patients with confirmed H. pylori infection in 55 clinical sites across the U.S. If successful
Read more →RDHLRedHill Biopharma Reports Second Quarter 2018 Financial Results and Provides Update on Operations
Top-line results from confirmatory Phase III study with TALICIA® for H. pylori infection on track to be announced in the fourth quarter of 2018 Positive top-line results from Phase III study with RHB-104 for Crohn’s disease - the study successfully met both its primary endpoint
Read more →RDHLRedHill Biopharma to Host Second Quarter 2018 Financial Results Conference Call on August 30, 2018
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, to
Read more →RDHLRedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation
Once granted, the new formulation patent is expected to be valid until at least 2033 RHB-106 is an encapsulated bowel preparation with worldwide rights licensed to Salix Pharmaceuticals RedHill and Salix recently amended their license agreement to include certain development ac
Read more →RDHLRedHill Biopharma Announces Closing of $25 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, to
Read more →RDHLRedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, to
Read more →RDHLRedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases,
Read more →RDHLRedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013) Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104 RedHill to host conference call and live w
Read more →RDHLRedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi
Mytesi® is an FDA-approved anti-diarrheal prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy (ART) Mytesi® is the fourth product being promoted by RedHill's gastrointestinal-focused U.S. sales forc
Read more →RDHLRedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA for H. pylori Infection
400 of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA® for H. pylori infection (ERADICATE Hp2) RedHill expects to complete enrollment in the Phase III ERADICATE Hp2 study in coming weeks and announce top-line re
Read more →RDHLRedHill Biopharma Announces Uplisting to Nasdaq Global Market
TEL-AVIV, Israel and RALEIGH, N.C., July 23, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
RedHill has received Notices of Allowance for two new patents covering RHB-104 in the U.S. and Europe which are expected to be valid until at least 2029, once granted Top-line results from the first Phase III study with RHB-104 for Crohn’s disease are expected to be announced in
Read more →RDHLRedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi
RedHill has been granted the exclusive right to co-promote Mytesi® (crofelemer 125 mg delayed-release tablets) in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by Napo Pharmaceuticals, a subsidiary o
Read more →RDHLRedHill Biopharma to Present Positive Phase II Results of BEKINDA for IBS-D at Digestive Disease Week 2018
TEL-AVIV, Israel and RALEIGH, N.C., May 30, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy
TEL-AVIV, Israel and RALEIGH, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn’s Disease on May 15
Last patient completed treatment for primary endpoint assessment in the Phase III study with RHB-104 for Crohn’s disease; Top-line results expected to be announced in approximately 3 months TEL-AVIV, Israel and RALEIGH, N.C., May 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Lt
Read more →RDHLRedHill Biopharma Reports First Quarter 2018 Financial Results
Top-line results from Phase III study with RHB-104 for Crohn’s disease (MAP US study) expected in approximately 3 months Top-line results from confirmatory Phase III study with TALICIA® for H. pylori infection (ERADICATE Hp2 study) expected Q4/2018 Net revenues of $2.4 million
Read more →RDHLRedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease
Top-line results from the Phase III study with RHB-104 for Crohn’s disease are expected to be announced in approximately three months Worldwide sales of Crohn’s disease therapies are estimated to exceed $10 billion in 2018 Top-line results from the confirmatory Phase III study
Read more →RDHLRedHill Biopharma Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA for H. pylori Infection
Approximately 70% of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA® for H. pylori infection (ERADICATE Hp2) RedHill expects to complete enrollment in Q3/2018 and announce top-line results in Q4/2018 The study
Read more →RDHLRedHill Biopharma to Host First Quarter 2018 Financial Results Conference Call on May 8, 2018
TEL-AVIV, Israel and RALEIGH, N.C., May 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Provides Semi-Annual Business Update
TEL-AVIV, Israel and RALEIGH, N.C., April 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercializatio
Read more →RDHLRedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting
TEL-AVIV, Israel and RALEIGH, N.C., March 27, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercializatio
Read more →RDHLRedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA for IBS-D
TEL-AVIV, Israel and RALEIGH, N.C., March 26, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercializatio
Read more →RDHLRedHill Biopharma to Present at H.C. Wainwright Annual Global Life Sciences Conference
TEL-AVIV, Israel and RALEIGH, N.C., March 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercializatio
Read more →RDHLRedHill Biopharma Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual Meeting
Data from non-clinical studies indicated that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON), is a potent and specific inhibitor of five human serine proteases, suggesting new potential therapeutic applications in oncology and inflammatory digestive diseases TEL-AV
Read more →RDHLRedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update
Top-line results from the Phase III study with RHB-104 for Crohn’s disease expected in mid-2018 Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori infection expected in the second half of 2018 Net revenues of $2 million and gross profit of $1.1 m
Read more →RDHLRedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma to Present at BIO CEO & Investor Conference
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma and Express Scripts Subsidiary Inside Rx Add EnteraGam to Savings Program for Uninsured or Underinsured Patients
TEL-AVIV, Israel and RALEIGH, N.C., Jan. 17, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces Final Results from Phase II Study with BEKINDA for IBS-D
TEL-AVIV, Israel and RALEIGH, N.C., Jan. 16, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA ) for Cholangiocarcinoma at Mayo Clinic and MD Anderson
YELIVA®, a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the treatment of cholangiocarcinoma Cholangiocarcinoma (bile duct cancer) is a highly lethal malignancy for which there is an urgent need for more effective treatments A Phase I cl
Read more →RDHLRedHill Biopharma Provides 2017 Year-End Business Update
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Reports 2017 Third Quarter Financial Results
RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017 In addition, an underwritten public offering of the Company’s American Depositary Shares (ADSs) is scheduled to be closed today, November 13, 2017, subject to customar
Read more →RDHLRedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease
Top-line results are expected to be announced in mid-2018 The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is evaluating the safety and efficacy of RHB-104 in 331 subjects with moderately to se
Read more →RDHLRedHill Biopharma Prices Public Offering of its American Depositary Shares
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 08, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma to Host Third Quarter 2017 Financial Results Conference Call on November 13, 2017
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces EnteraGam Poster Presentation at the ISPOR 20th Annual European Congress
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT for Migraines
RIZAPORT® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines A Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first half of 2018, if the submission is deemed complete and permits a full review RI
Read more →RDHLRedHill Biopharma to Present at the BIO-Europe 2017 Conference
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 26, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104
The new patent, covering RHB-104 for relapsing-remitting multiple sclerosis (MS), is expected to be valid until 2032, once granted Enrollment in the Phase III study with RHB-104 for Crohn’s disease to be completed in November 2017 and top-line results expected in Q3/2018 A pivo
Read more →RDHLRedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer
RedHill to benefit from various incentives to develop MESUPRON (upamostat) for the adjuvant treatment of pancreatic cancer, including a seven-year marketing exclusivity period for the indication, if approved MESUPRON is a proprietary, first-in-class, orally-administered protease
Read more →RDHLRedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 19, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma to Present at the BioNetwork 2017 Partnering Summit
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 10, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
BEKINDA®i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan® (rifaximin) and Viberzi®
Read more →RDHLRedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018
RedHill has curtailed the target sample size in the ongoing first Phase III study with RHB-104 for Crohn’s disease (MAP US) from 410 to approximately 325 subjects, of which 322 have been enrolled to date, while maintaining statistical power of over 80% with a treatment effect of
Read more →RDHLRedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 28, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercializatio
Read more →RDHLRedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercializatio
Read more →RDHLRedHill Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercializatio
Read more →RDHLRedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.
Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions PPIs are one of the
Read more →RDHLRedHill Biopharma to Present at the 10th Annual BioPharm America International Partnering Conference
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercializatio
Read more →RDHLRedHill Biopharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 31, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indic
Read more →RDHLRedHill Biopharma Provides 2017 Semi-Annual Business Update
RedHill’s U.S. gastrointestinal (GI)-focused sales force is promoting two specialty products, setting the stage for the potential launch of RedHill’s late clinical-stage GI products, if approved, and for the acquisition of additional commercial GI products The ERADICATE Hp2 conf
Read more →RDHLRedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease
The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US study To date, over 300 of the planned 410 subjects, have been
Read more →RDHLRedHill Biopharma Reports 2017 Second Quarter Financial Results
RedHill maintains a debt-free balance sheet with $51 million cash1 at the end of the second quarter of 2017 Select recent milestones include: Initial net revenues of approximately $0.5 million between June 12-30 following commencement of promotional activities in the U.S. by Re
Read more →RDHLRedHill Biopharma to Host Second Quarter 2017 Financial Results Conference Call on July 25, 2017
TEL-AVIV, Israel and RALEIGH, N.C., July 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces Last Patient Visit in BEKINDA Phase II Study for IBS-D
Top-line results are expected in September 2017 The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D), with a primary endpo
Read more →RDHLRedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease
The second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn’s disease (MAP US study) is planned to be held in late July 2017 and will assess the safety and efficacy of RHB-104 in the first 222 subjects who have completed week 26
Read more →RDHLRedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
TEL-AVIV, Israel and RALEIGH, N.C., June 19, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization
Read more →RDHLRedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA™) for H. pylori Infection
Subject to a successful outcome and any additional regulatory feedback, the confirmatory Phase III study (ERADICATE Hp 2) is expected to complete the package required for a potential U.S. NDA for RHB-105, newly branded as TALICIA™ The two-arm, randomized, double-blind, active co
Read more →RDHLRedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
The positive Phase III top-line results indicate that the study successfully met its primary endpoint and BEKINDA® 24 mg was shown to be effective, safe and well tolerated in patients with acute gastroenteritis and gastritis RedHill will host a conference call and webcast to dis
Read more →RDHLRedHill Biopharma Initiates Promotion of Donnatal and EnteraGam in the U.S.
RedHill has initiated commercial activities in the U.S. with its gastrointestinal-focused sales force, promoting two gastrointestinal specialty products, Donnatal® and EnteraGam® TEL-AVIV, Israel and RALEIGH, N.C., June 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ
Read more →RDHLRedHill Biopharma to Present at the 2017 BIO International Convention
TEL-AVIV, Israel, June 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprieta
Read more →RDHLRedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017
TEL-AVIV, Israel, May 04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administe
Read more →RDHLRedHill Biopharma Reports 2017 First Quarter Financial Results
RedHill maintains a debt-free balance sheet with a $61 million cash balance1 at the end of the first quarter of 2017, allowing the Company to continue to diligently execute its development and U.S. commercialization plans Select recent milestones include: Exclusive U.S. co-prom
Read more →RDHLRedHill Biopharma to Host First Quarter 2017 Financial Results Conference Call on May 3, 2017
TEL-AVIV, Israel, April 25, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, propriet
Read more →RDHLRedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D
Top-line results are expected in the third quarter of 2017 The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D) IBS is on
Read more →RDHLRedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA Phase I Study Results in Advanced Solid Tumors
The article was authored by scientists from the Medical University of South Carolina (MUSC) Hollings Cancer Center and Apogee Biotechnology and was published in Clinical Cancer Research The Phase I study with YELIVA® in patients with advanced solid tumors successfully met its pr
Read more →RDHLRedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D
The R&D Day on BEKINDA® will take place on Thursday, April 27, 2017 in NYC from 8:00-10:00 EDT; A live webcast will be available through RedHill’s website Top-line results from a Phase III study with BEKINDA® 24 mg for acute gastroenteritis and gastritis are expected in Q2/2017
Read more →RDHLRedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA
RedHill received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA® (RHB-102), expected to be valid until at least 2034, once granted BEKINDA® is a proprietary, bimodal extended-release, once-daily oral pill form
Read more →RDHLRedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT for Migraines in Luxembourg
The national marketing approval in Luxembourg completes the current approval process of RIZAPORT® under the European Decentralized Procedure (DCP); RIZAPORT® is also approved for marketing in Germany and a national Marketing Authorization Application (MAA) has been submitted in S
Read more →RDHLRedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam
RedHill expects to initiate U.S. promotion of its two commercially-available gastrointestinal specialty products, Donnatal®1 and EnteraGam®2, in mid-2017 Under the terms of the agreement, RedHill will pay Entera Health royalties on net sales generated from the sale of EnteraGam®
Read more →RDHLRedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA for the Treatment of Cholangiocarcinoma
Orphan Drug designation allows RedHill to benefit from various development incentives to develop YELIVA® (ABC294640) for cholangiocarcinoma, as well as a seven-year marketing exclusivity period for the indication, if approved for marketing A Phase IIa clinical study with YELIVA®
Read more →RDHLRedHill Biopharma to Present at BioCentury Future Leaders in the Biotech Industry Conference
TEL-AVIV, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, propriet
Read more →RDHLRedHill Biopharma to Present at the 2017 MAP Conference
TEL-AVIV, Israel, March 22, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, propriet
Read more →RDHLRedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease
A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countries The open-label extension study (the MAP US2 study) is intended to assess the safety
Read more →RDHLRedHill Biopharma to Present at the BIO-Europe Spring 2017 Conference
TEL-AVIV, Israel, March 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-adminis
Read more →RDHLRedHill Biopharma’s Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating to Donnatal
RedHill and Concordia recently entered into an exclusive co-promotion agreement, granting RedHill certain promotion rights in the U.S. for Donnatal® RedHill expects to initiate promotion of Donnatal® in the second quarter of 2017 TEL-AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE
Read more →RDHLRedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website
TEL-AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administ
Read more →RDHLRedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results
RedHill maintains a strong and debt-free balance sheet with approximately $66 million in cash and cash equivalents at the end of 2016, allowing the Company to continue to execute its development and U.S. commercialization plans Select 2016 milestones include: Successful final r
Read more →RDHLRedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
Top-line results are expected in the second quarter of 2017 The randomized, double-blind, placebo-controlled Phase III study is evaluating the safety and efficacy of BEKINDA® 24 mg in patients with acute gastroenteritis and gastritis (the GUARD study) Acute gastroenteritis and
Read more →RDHLRedHill Biopharma to Host Fourth Quarter and Full-Year 2016 Financial Results Conference Call on February 23, 2017
TEL-AVIV, Israel, Feb. 16, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administ
Read more →RDHLRedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
Top-line results are expected in the second quarter of 2017 The randomized, double-blind, placebo-controlled Phase III study is evaluating the safety and efficacy of BEKINDA® 24mg in patients with acute gastroenteritis and gastritis (the GUARD study) Acute gastroenteritis and g
Read more →RDHLRedHill Biopharma to Present at the BIO CEO & Investor Conference
TEL-AVIV, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administ
Read more →RDHLRedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections
RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection Under FDA's Generating Antibiotic Incentives Now (GAIN) Act, QIDP designation allows for Fast-Track status and Priori
Read more →RDHLRedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection
The first group of subjects have been dosed in a single-dose three-way crossover pharmacokinetic (PK) study with RHB-105 versus the active comparators in the confirmatory Phase III study and in a food-effect study with RHB-105 in healthy volunteers The confirmatory Phase III stu
Read more →RDHLRedHill Biopharma’s RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium
TEL-AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administ
Read more →RDHLRedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management
Members of RedHill’s Board of Directors, senior management and Advisory Board have exercised stock options to purchase an aggregate of 1,700,000 ordinary shares (equivalent to 170,000 American Depositary Shares (ADSs)) during the last week Following issuance of the ordinary shar
Read more →RDHLRedHill Biopharma Announces YELIVA (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference
The abstract, to be presented at the upcoming 2017 Cholangiocarcinoma Foundation Annual Conference, describes positive findings from non-clinical studies and the Phase I clinical study with YELIVA® (ABC294640), suggesting that YELIVA® may be an effective drug for the treatment of
Read more →RDHLRedHill Biopharma Announces New Research Collaboration with Aarhus University for Oncology Drug MESUPRON
The new research collaboration follows previous non-clinical studies conducted with Denmark’s Aarhus University and is designed to identify additional high affinity molecular targets of MESUPRON (upamostat) Further evaluation of MESUPRON, together with Aarhus University, may all
Read more →RDHLRedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium
TEL-AVIV, Israel, Jan. 04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administ
Read more →RDHLRedHill Biopharma Announces Exercise of Underwriters’ Option
TEL-AVIV, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administ
Read more →RDHLRedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal
RedHill and Concordia entered into an exclusive co-promotion agreement, granting RedHill certain U.S. promotion rights for Donnatal® Donnatal®1, Tablets and Elixir (syrup), is a prescription oral drug used with other drugs for the treatment of irritable bowel syndrome (IBS) and
Read more →RDHLRedHill Biopharma to Present at the Biotech Showcase 2017
TEL-AVIV, Israel, Dec. 28, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters
TEL-AVIV, Israel, Dec. 27, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, smal
Read more →RDHLRedHill Biopharma Prices Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants
TEL-AVIV, Israel, Dec. 21, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, smal
Read more →RDHLRedHill Biopharma Announces Proposed Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants
TEL-AVIV, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, smal
Read more →RDHLRedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA for Multiple Myeloma
The first patients have been screened and a first patient has been dosed in the open-label, dose escalation Phase Ib/II study with YELIVA® (ABC294640) for multiple myeloma The Phase Ib/II clinical study is intended to evaluate the safety and efficacy of YELIVA® in up to 77 patie
Read more →RDHLRedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT for Migraines with Pharmatronic Co. in South Korea
RedHill and its co-development partner, IntelGenx Corp. (IntelGenx), have signed a definitive agreement with Pharmatronic Co., granting an exclusive license to commercialize the acute migraine drug RIZAPORT® in South Korea This agreement follows the previously announced commerci
Read more →RDHLRedHill Biopharma Announces Positive and Unanimous DSMB Recommendation for Continuation of Phase III Study with RHB-104 for Crohn’s Disease
Following a pre-planned review of safety data, RedHill has received a unanimous recommendation from the independent Data and Safety Monitoring Board (DSMB) to continue the MAP US Phase III study with RHB-104 for Crohn’s disease as planned, without any modifications A second DSMB
Read more →RDHLRedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential of RHB-104 in Multiple Sclerosis
Thought to be autoimmune in nature, the multiple sclerosis (MS) inflammatory process is also consistent with an infectious disease; The CEASE-MS Phase IIa proof-of-concept (PoC), single-arm, open-label study was designed with a series of exploratory endpoints to evaluate the safe
Read more →RDHLRedHill Biopharma to Present at the Jefferies Microbiome Summit
TEL-AVIV, Israel, Dec. 05, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
The poster, to be presented at the upcoming EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, describes results from non-clinical studies conducted by Apogee Biotechnology Corp. demonstrating the potential antitumor and anti-inflammatory effects of YELIVA™ (ABC2
Read more →RDHLRedHill Biopharma to Present at the German Equity Forum 2016
TEL-AVIV, Israel, Nov. 16, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma Reports 2016 Third Quarter Financial Results
RedHill maintains a debt-free balance sheet with $40.5 million in cash at the end of the third quarter, allowing the Company to continue to diligently execute its three ongoing Phase III gastrointestinal disease programs and other clinical-stage programs Recent key milestones in
Read more →RDHLRedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study
The confirmatory Phase III study with RHB-105 for H. pylori infection is planned to be initiated in H1/2017, after completion of the ongoing supportive PK program; Subject to a successful outcome, the confirmatory Phase III study and the supportive PK program are expected to comp
Read more →RDHLRedHill Biopharma to Host Third Quarter 2016 Financial Results Conference Call on November 14, 2016
TEL-AVIV, Israel, Nov. 07, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma to Present at the Jefferies 2016 London Healthcare Conference
TEL-AVIV, Israel, Nov. 07, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results
Top-line results from both the ongoing Phase III clinical study for acute gastroenteritis and gastritis and the ongoing Phase II clinical study for diarrhea-predominant irritable bowel syndrome (IBS-D) are expected in mid-2017 Over two-thirds of the planned total of 320 subjects
Read more →RDHLRedHill Biopharma Announces Withdrawal of Public Offering of its American Depositary Shares
TEL-AVIV, Israel, Nov. 02, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, smal
Read more →RDHLRedHill Biopharma to Host Investor Conference Call Today at 18:00 EDT Following Announcement of Proposed Public Offering of its American Depository Shares
TEL-AVIV, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, smal
Read more →RDHLRedHill Biopharma Announces Proposed Public Offering of its American Depository Shares
TEL-AVIV, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, smal
Read more →RDHLRedHill Biopharma to Present at the BIO-Europe 2016 Conference
TEL-AVIV, Israel, Oct. 31, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma Announces Allowance of a Patent in Japan Supporting RHB-104 for Multiple Sclerosis
RedHill has received from the Japan Patent Office a Notice of Allowance for a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once granted RedHill’s robust RHB-104 patent portfolio covering its oral antibiotic combination therapy include
Read more →RDHLRedHill Biopharma to Present at the BIO Investor Forum 2016
TEL-AVIV, Israel, Oct. 13, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma to Host Webcast Today at 8:30 am EDT Following Announcement of Progress Update on RHB-104 Phase III Crohn’s Disease Program Including the Introduction of an Option for Early Stop for Success in Q2/2017
TEL-AVIV, Israel, Oct. 06, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma Provides Progress Update on RHB-104 Phase III Crohn’s Disease Program and Introduces Option for Early Stop for Success in Q2/2017
An option for early stop for success for overwhelming efficacy has been introduced into the ongoing first Phase III study with RHB-104 for Crohn’s disease (the “MAP US” study) and analysis is expected in the second quarter of 2017 as part of a second independent data safety and m
Read more →RDHLRedHill Biopharma Announces Initiation of Phase II Study with YELIVA™ in Hepatocellular Carcinoma at the Medical University of South Carolina
The Phase II clinical study is intended to evaluate the efficacy and safety of YELIVA™ (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), the most common primary malignant cancer of the liver with a worldwide mortality rate of 95% The Phase II study is being c
Read more →RDHLRedHill Biopharma to Present at the BioNetwork West 2016 Partnering Summit
TEL-AVIV, Israel, Sept. 27, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small m
Read more →RDHLRedHill Biopharma and IntelGenx Announce RIZAPORT Commercialization Term Sheet with Pharmatronic Co. for Korea
RIZAPORT® (5 mg and 10 mg) was granted marketing approval in Germany under the European Decentralized Procedure (DCP) This binding term sheet for the license of RIZAPORT® in South Korea follows a recent commercialization agreement for Spain with Grupo JUSTE S.A.Q.F, who recently
Read more →RDHLRedHill Biopharma Announces Research Collaboration with Stanford University for YELIVA™
TEL-AVIV, Israel, Sept. 12, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small m
Read more →RDHLRedHill Biopharma Announces Phase Ib/II Study with YELIVA™ Initiated for Multiple Myeloma at a Leading U.S. Academic Medical Center
The Phase Ib/II clinical study is intended to evaluate the safety and efficacy of YELIVA™ (ABC294640) in patients with refractory or relapsed multiple myeloma and is supported by a $2 million grant from the National Cancer Institute (NCI), awarded to Apogee Biotechnology Corp., w
Read more →RDHLRedHill Biopharma to Present at the 9th Annual BioPharm America International Partnering Conference
TEL-AVIV, Israel, Sept. 01, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small m
Read more →RDHLRedHill Biopharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
TEL-AVIV, Israel, Aug. 31, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma Announces Approval of a European Patent Supporting RHB-104 for Multiple Sclerosis
RedHill has received from the European Patent Office a Notice of Intention to Grant a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once granted A Phase IIa proof-of-concept study evaluating RHB-104 in patients treated for relapsing-re
Read more →RDHLRedHill Biopharma Provides 2016 Semi-Annual R&D Update
TEL-AVIV, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis
The Phase IIa proof-of-concept study evaluates the safety and potential efficacy of fixed oral dose RHB-104 as an add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (RRMS) Analysis of the study is ongoing, with top-line final results expected in the
Read more →RDHLRedHill Biopharma Reports 2016 Second Quarter Financial Results
RedHill maintains a strong and debt-free balance sheet with $47.7 million in cash at the end of the second quarter, allowing the Company to continue to diligently execute its three ongoing Phase III gastrointestinal disease programs in the U.S. as well as additional clinical prog
Read more →RDHLRedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection
RedHill has received a Notice of Allowance for an additional U.S. patent covering RHB-105, expected to be valid until 2034 once granted The planned confirmatory Phase III study with RHB-105 for the treatment of H. pylori infection, if successful, is expected to support a U.S. Ne
Read more →RDHLRedHill Biopharma to Host Second Quarter 2016 Financial Results Conference Call on July 26, 2016
TEL-AVIV, Israel, July 19, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma Announces Research Collaboration with NIH for Potential Ebola Treatment
TEL-AVIV, Israel, July 13, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT™ for Migraines with Grupo JUSTE in Spain and Additional Potential Territories
RedHill and its co-development partner, IntelGenx, have signed a definitive agreement with Grupo JUSTE granting an exclusive license to commercialize their acute migraine drug RIZAPORT™ in Spain, and a right of first refusal for additional territories Grupo JUSTE is a prominent
Read more →RDHLRedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection
The peer-reviewed article, authored by scientists from the University of Central Florida, concludes that the triple combination of the RHB-104 active components provides excellent synergistic activity in the inhibition of mycobacterial growth, potentially leading to a new and eff
Read more →RDHLRedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA™ in Advanced Solid Tumors
Final results from the Phase I study with YELIVA™ (ABC294640) in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina (MUSC), successfully met its primary and secondary endpoints, demonstrating that the drug is well t
Read more →RDHLRedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA™ for IBS-D
The first patients have been dosed in the randomized, double-blind, placebo-controlled Phase II study with BEKINDA™ 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in 120 subjects in 12 clinical sites in the U.S. IBS is one of the most common gas
Read more →RDHLRedHill Biopharma to Present at JMP Securities Life Sciences Conference
TEL-AVIV, Israel, June 15, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mo
Read more →RDHLRedHill Biopharma to Present at the 2016 BIO International Convention
TEL-AVIV, Israel, May 31, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mol
Read more →RDHLRedHill Biopharma to Present at Jefferies 2016 Healthcare Conference
TEL-AVIV, Israel, May 30, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small mol
Read more →RDHLRedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study
The $1.8 million U.S. National Cancer Institute (NCI) grant, awarded to the Medical University of South Carolina (MUSC), is intended to support a research program covering a variety of solid tumor cancers, including a Phase II study with YELIVA™ (ABC294640) for the treatment of a
Read more →RDHLRedHill Biopharma to Present at BioNetwork East 2016 Partnering Summit
TEL-AVIV, Israel, April 25, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, sma
Read more →RDHLRedHill Biopharma Reports 2016 First Quarter Financial Results
RedHill maintains a strong and debt-free balance sheet with approximately $53 million in cash at the end of the first quarter, allowing the Company to continue to diligently execute its strategic and operational plans, including its three ongoing Phase III gastrointestinal diseas
Read more →RDHLRedHill Biopharma to Participate in the FBR & Co. Healthcare Series Focused on Infectious Diseases
TEL-AVIV, Israel, April 19, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small m
Read more →RDHLRedHill Biopharma Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection
The FDA has confirmed, subject to final minutes of the meeting, the planned two-arm, randomized, double-blind, active comparator design of the confirmatory Phase III study with RHB-105 for the treatment of H. pylori infection, expected to be initiated in the second half of 2016
Read more →RDHLRedHill Biopharma to Host First Quarter 2016 Financial Results Conference Call on April 20, 2016
TEL-AVIV, Israel, April 13, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small m
Read more →RDHLRedHill Biopharma Initiates Phase II Study of BEKINDA™ for Irritable Bowel Syndrome
The randomized, double-blind, 2-arm parallel group Phase II study of BEKINDA™ 12 mg is expected to enroll 120 patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D) in 12 clinical sites in the U.S. The U.S. potential market for IBS-D treatments is estimate
Read more →RDHLRedHill Biopharma Announces Interim Results from Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis
The ongoing CEASE-MS Phase IIa proof-of-concept (PoC), single-arm, open-label study was designed with a series of exploratory endpoints to evaluate the safety and potential efficacy of fixed oral dose RHB-104 as add-on therapy to interferon beta-1a in 18 patients treated for rela
Read more →RDHLRedHill Biopharma and IntelGenx Announce RIZAPORT™ Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories
RedHill and its co-development partner, IntelGenx Corp., have entered into a binding term sheet with Grupo JUSTE granting an exclusive license to commercialize their acute migraine drug RIZAPORT™ in Spain, and a right of first refusal for additional territories Grupo JUSTE is a
Read more →RDHLRedHill Biopharma to Present at Bio-Europe Spring 2016 Conference
TEL-AVIV, Israel, March 28, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, sma
Read more →RDHLRedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential of YELIVA™ in Cholangiocarcinoma Cancer
The article was authored by scientists from the Mayo Clinic Cancer Center, the Hollings Cancer Center at the Medical University of South Carolina and Apogee Biotechnology Corporation RedHill announced in October 2015 positive top-line results from a Phase I study with YELIVA™ (A
Read more →RDHLRedHill Biopharma to Present at the 28th Annual ROTH Conference
TEL-AVIV, Israel, March 09, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, sma
Read more →RDHLRedHill Biopharma Reports Successful Final Results of Phase III Study With RHB-105 for H. pylori Infection
The RHB-105 first Phase III Clinical Study Report demonstrates the efficacy and safety of RHB-105 in eradication of H. pylori infection, supports the potential superior efficacy of RHB-105 over current standard-of-care therapies and confirms the positive top-line results previous
Read more →RDHLRedHill Biopharma Provides 2016 R&D Update
RedHill’s advanced pipeline includes three Phase III programs, several Phase II programs and additional early-stage programs. RedHill maintains a strong and debt-free balance sheet, allowing the Company to continue to execute its development plans. Key potential highlights for
Read more →RDHLRedHill Biopharma Reports 2015 Fourth Quarter and Full-Year Financial Results
Key Highlights Include: RedHill maintains a strong and debt-free balance sheet with approximately $58 million in cash and cash equivalents at the end of 2015, allowing the Company to continue to execute its development plans Key milestones in 2015 include positive top-line resu
Read more →RDHLRedHill Biopharma Announces Notice of Allowance for U.S. Patent Covering RIZAPORT™ for Migraines
The new U.S. patent is expected to be valid until 2034, once granted RedHill and its co-development partner, IntelGenx Corp., recently announced the national approval of RIZAPORT™ in Germany under the European Decentralized Procedure (DCP) RedHill and IntelGenx continue to work
Read more →RDHLRedHill Biopharma to Host 2015 Fourth Quarter and Year-End Financial Results Conference Call on February 25, 2016
TEL-AVIV, Israel, Feb. 18, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administe
Read more →RDHLRedHill Biopharma Appoints Dr. June S. Almenoff and Ms. Theresa M. Stevens to Advisory Board
Dr. Almenoff previously served as President, Principal Executive Officer and Chief Medical Officer of Furiex Pharmaceuticals (now Actavis plc) Ms. Stevens previously served as Chief Corporate Development Officer and Senior Vice President at Aptalis Pharma (now Actavis plc) TEL-
Read more →RDHLRedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 mg and Submission to FDA of IBS-D Phase II Study Protocol
RedHill recently concluded a successful first-in-man pharmacokinetic (PK) study with BEKINDA™ 12 mg (RHB-102) proprietary formulation, to support the planned Phase II study for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) RedHill submitted to the FDA th
Read more →RDHLRedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent Covering RHB-104 Phase III Crohn’s Disease Program
Once granted, the new U.S. patent covering methods of use for RHB-104 is expected to be valid through 2029 RHB-104 is undergoing a first Phase III study for the treatment of Crohn’s disease in the U.S. and additional countries, with interim analysis expected during the second ha
Read more →RDHLRedHill Biopharma Issues Letter to Shareholders
TEL-AVIV, Israel, Feb. 09, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administe
Read more →RDHLRedHill Biopharma Announces Collaboration With Germany’s Fraunhofer Institute for Oncology Drug RP101
TEL-AVIV, Israel, Feb. 08, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administe
Read more →RDHLRedHill Biopharma to Present at the 18th Annual BIO CEO & Investor Conference
TEL-AVIV, Israel, Feb. 02, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administe
Read more →RDHLRedHill Biopharma to Present at Biotech Showcase 2016
TEL-AVIV, Israel, Jan. 05, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administe
Read more →RDHLRedHill Biopharma Announces Appointment of Micha Ben Chorin as Chief Financial Officer
TEL-AVIV, Israel, Dec. 30, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administe
Read more →RDHLRedHill Biopharma Announces Appointment of Rick D. Scruggs to Board of Directors
TEL-AVIV, Israel, Dec. 15, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administe
Read more →RDHLRedHill Biopharma Announces Completion of Dosing in Phase IIa Study of RHB-104 for Multiple Sclerosis
Top-line interim results from the Phase IIa proof-of-concept clinical study of RHB-104 in patients treated for relapsing-remitting multiple sclerosis (the CEASE-MS study) are expected by early Q1/2016 The Phase IIa study is intended to evaluate the safety and efficacy of RHB-104
Read more →RDHLRedHill Biopharma Announces Passing of Board Member Alicia Rotbard
TEL-AVIV, Israel, Nov. 30, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administe
Read more →RDHLRedHill Biopharma to Present at the Jefferies Autumn 2015 Global Healthcare Conference
TEL-AVIV, Israel, Nov. 12, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Reports Results for the Third Quarter of 2015
Key Highlights Include: A strong cash position of approximately $64 million at the end of the third quarter of 2015 following the Company's July 2015 public offering in the U.S. with gross proceeds of $44.5 million Recent key milestones include the first European marketing appr
Read more →RDHLRedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
The German Federal Institute for Drugs and Medical Devices (BfArM) has granted national marketing approval for RIZAPORT (RHB-103) for the treatment of acute migraines under the European Decentralized Procedure (DCP) RedHill and IntelGenx continue their close cooperation in order
Read more →RDHLRedHill Biopharma to Host Third Quarter 2015 Financial Results Conference Call on November 9, 2015
TEL-AVIV, Israel, Oct. 29, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma to Present at the BIO-Europe 2015 Conference
TEL-AVIV, Israel, Oct. 28, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Announces Positive Top-line Results from YELIVA(TM) (ABC294640) Phase I Study in Advanced Solid Tumors
The Phase I study with YELIVA (ABC294640) successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic act
Read more →RDHLRedHill Biopharma to Present at Gelbart-Kahana Biomed Conference on October 25, 2015
TEL-AVIV, Israel, Oct. 22, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Announces Planned Management Changes
TEL-AVIV, Israel, Oct. 22, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Announces National Cancer Institute Grant Awarded to Apogee Biotechnology Corp. for YELIVA(TM) (ABC294640) Prostate Cancer Research
The $225,000 U.S. National Cancer Institute ("NCI") grant was awarded to Apogee Biotechnology Corporation, from which RedHill acquired the exclusive worldwide rights to YELIVA (ABC294640) in March 2015 A Phase I/II study with YELIVA (ABC294640) was recently initiated in the U.S.
Read more →RDHLRedHill Biopharma to Present at the BioNetwork West Partnering Summit
TEL-AVIV, Israel, Oct. 19, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Provides Update on BEKINDA(TM) Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D
Based on recent U.S. FDA feedback and prior feedback from the UK MHRA, RedHill believes that the ongoing Phase III study with BEKINDA for gastroenteritis (the GUARD study) may be sufficient as a single study to support the filing of a marketing application in the U.S. and Europe,
Read more →RDHLRedHill Biopharma and IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application is Approvable Under the European Decentralized Procedure
The German Federal Institute for Drugs and Medical Devices (BfArM) has confirmed the positive outcome of the European Decentralized Procedure and informed RedHill and IntelGenx that the European Marketing Authorization Application (MAA) for RIZAPORT (RHB-103) is approvable RedHi
Read more →RDHLRedHill Biopharma Announces $2 Million National Cancer Institute Grant for YELIVA(TM) (ABC294640) Phase II Study for Multiple Myeloma
The National Cancer Institute (NCI) $2 million grant is intended to support the Phase II study with YELIVA (ABC294640) for refractory or relapsed multiple myeloma, planned to be initiated by RedHill at Duke University Medical Center by the end of 2015 YELIVA (ABC294640) is a pro
Read more →RDHLRedHill Biopharma Announces Standard-of-Care Eradication Data From the RHB-105 Phase III Study Further Supporting the Study's Positive Results
Patients enrolled in the placebo arm of the ERADICATE Hp Phase III study received open-label standard-of-care (SoC) therapy for persistent Helicobacter pylori (H. pylori) infection; results from this group demonstrated a 63% H. pylori eradication rate, compared to the previously
Read more →RDHLRedHill Biopharma to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
TEL-AVIV, Israel, Sept. 2, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Announces Last Patient Visit in the Phase I Study With YELIVA(TM) (ABC294640) for Advanced Solid Tumors
The open-label, dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) Phase I study with YELIVA (ABC294640) in patients with advanced solid tumors was supported by grants from the National Cancer Institute (NCI) and the FDA's Office of Orphan Products Development (OOPD)
Read more →RDHLRedHill Biopharma Receives Notice of Allowance for New Israeli Patent Covering RHB-104 for the Treatment of Crohn's Disease
Once granted, the new Israeli patent is expected to be valid through at least 2029, further extending RedHill's global patent portfolio covering RHB-104 RHB-104 is undergoing a first Phase III study for the treatment of Crohn's disease in the U.S. and additional countries (the M
Read more →RDHLRedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential of ABC294640 (YELIVA(TM)) in Prostate Cancer
The publication in the peer-reviewed journal Molecular Cancer Research details promising pre-clinical results suggesting ABC294640 significantly inhibits prostate cancer tumor growth RedHill filed a trademark application with the U.S. Patent and Trademark Office for the new bran
Read more →RDHLRedHill Biopharma to Present RHB-104 Phase III Crohn's Program at the International Research Symposium on Crohn's Disease
TEL-AVIV, Israel, Aug. 12, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Reports Results for the Second Quarter of 2015
Key Highlights Include: Strong cash position of approximately $26.6 million at the end of the second quarter of 2015 and approximately $66 million as of July 28, 2015, following the Company's July 2015 public offering in the U.S. Gross proceeds of $44.5 million from the Company
Read more →RDHLRedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals
Salix Pharmaceuticals, recently acquired by Valeant Pharmaceuticals, confirmed to RedHill that it continues the development of RedHill's RHB-106 encapsulated bowel preparation Salix further clarified to RedHill that the purgative tablet formulation referenced in Valeant's second
Read more →RDHLRedHill Biopharma to Host Second Quarter 2015 Financial Results Conference Call on July 29, 2015
TEL-AVIV, Israel, July 23, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
TEL-AVIV, Israel, July 22, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Prices Public Offering of Its American Depository Shares
TEL-AVIV, Israel, July 16, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Announces Size of Proposed Public Offering of Its American Depository Shares
Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 15, 2015 Registration No. 333-193503 TEL-AVIV, Israel, July 15, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli
Read more →RDHLRedHill Biopharma Extends Option Agreement for Phase II-Stage Pancreatic Cancer Drug RP101
RedHill has extended the term of the exclusive option agreement for the oncology drug candidate RP101 for an additional year RP101 is a proprietary, first-in-class, orally-administered, heat shock protein 27 (Hsp27) inhibitor intended to prevent the induction of resistance to ch
Read more →RDHLRedHill Biopharma Announces Proposed Public Offering of Its American Depository Shares
TEL-AVIV, Israel, July 14, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma Receives Authorization in Australia and New Zealand for Ongoing Phase III Crohn's Disease Study With RHB-104
The Phase III study with RHB-104 for Crohn's disease is currently ongoing in the U.S. and additional countries, with up to 120 clinical sites planned globally (the MAP US study) A Clinical Trial Application for a second Phase III study with RHB-104 for Crohn's disease in Europe
Read more →RDHLRedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
Once granted, the two new U.S. patents covering RHB-104 are expected to be valid through 2029 RHB-104 is undergoing a first Phase III study for the treatment of Crohn's disease in the U.S. and additional countries A second Phase III study with RHB-104 for Crohn's disease is pla
Read more →RDHLRedHill Biopharma Initiates Phase I/II Study of ABC294640 for Refractory Lymphoma
The Phase I/II study, led by Dr. Chris Parsons, MD, associate professor at Louisiana State University Health Sciences Center, is intended to evaluate the safety and tolerability of ABC294640 in patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL), primarily pat
Read more →RDHLRedHill Biopharma Announces Acceptance of Phase III Trial Application in Europe with RHB-104 for Crohn's Disease
TEL-AVIV, Israel, June 16, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gast
Read more →RDHLRedHill Biopharma to Present at the 2015 BIO International Convention
TEL-AVIV, Israel, June 16, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammator
Read more →RDHLRedHill Biopharma to Host Conference Call Today to Review Positive Phase III Top-Line Results With RHB-105 for H. Pylori Infection
TEL-AVIV, Israel, June 15, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gast
Read more →RDHLRedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection
Top-line results from the RHB-105 Phase III study demonstrated 89.4% efficacy in eradicating H. pylori infection with RHB-105 The Phase III study successfully met its primary endpoint of superiority over historical standard of care efficacy levels of 70%, with high statistical s
Read more →RDHLRedHill Biopharma Announces Completion of Patient Enrollment in the Phase IIa Study of RHB-104 for Multiple Sclerosis
The last patient has been enrolled in the Phase IIa, proof-of-concept clinical study evaluating RHB-104 as an add-on therapy to interferon beta-1a in patients treated for relapsing-remitting multiple sclerosis (the CEASE-MS study) Interim results from the Phase IIa CEASE-MS stud
Read more →RDHLRedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study
Last patient has completed treatment course with RHB-105, for primary endpoint evaluation The Phase III top-line results with RHB-105 for the treatment of H. pylori bacterial infection are expected during the third week of June 2015, subject to completion of review requirements
Read more →RDHLRedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results
Key highlights and upcoming anticipated milestones include: Phase III top-line results with RHB-105 for the treatment of H. pylori bacterial infection are expected during the third week of June 2015, subject to completion of review requirements Phase III top-line results with B
Read more →RDHLRedHill Biopharma to Present at the Jefferies 2015 Global Healthcare Conference
TEL-AVIV, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointest
Read more →RDHLRedHill Biopharma's Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market
RedHill's Investor Webcast Forum, held on May 14, 2015, focused on the development program for RHB-105, currently undergoing a first Phase III study (ERADICATE Hp study) for the treatment of H. pylori bacterial infection, with top-line results expected in mid-end June 2015 Key o
Read more →RDHLRedHill Biopharma to Present at the BioTrinity 2015 Partnering Conference
TEL-AVIV, Israel, May 8, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gast
Read more →RDHLRedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study
RedHill will host an interactive investor forum on H. pylori bacterial infection and RHB-105, on Thursday, May 14, 2015, at 8:00-9:30 am Eastern Time. Participants are invited to join the forum through the Company's website or by telephone RHB-105 dosing has been completed in th
Read more →RDHLRedHill Biopharma to Present at the Oppenheimer 16th Annual Israeli Conference
TEL-AVIV, Israel, May 4, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointest
Read more →RDHLRedHill Biopharma Reports Results for the First Quarter of 2015
Key Highlights Include: Strong cash position of approximately $32.5 million at the end of the first quarter of 2015, following the closing of the Company's first public offering in the U.S. including participation by leading institutional healthcare investors Key milestones ach
Read more →RDHLRedHill Biopharma to Present at the BioNetwork East 2015 Partnering Conference
TEL-AVIV, Israel, April 28, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE: RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases
Read more →RDHLRedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection
The last patient has been enrolled in the ERADICATE Hp study - a randomized, placebo-controlled, first Phase III study evaluating RHB-105 as a first-line therapy for H. pylori bacterial infection, a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and MALT l
Read more →RDHLRedHill Biopharma to Host First Quarter 2015 Financial Results Conference Call on April 30, 2015
TEL-AVIV, Israel, April 21, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastroint
Read more →RDHLRedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment
The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new formulation patent application covering RHB-105 H. pylori bacterial infection treatment, to expire no earlier than 2034 Top-line results from the ongoing Phase III study with RHB-105 are expe
Read more →RDHLRedHill Biopharma Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech
ABC294640 is a proprietary, first-in-class, new chemical entity (NCE) sphingosine kinase-2 (SK2) inhibitor, administered orally, which has successfully completed numerous pre-clinical studies and a Phase I study in cancer patients with advanced solid tumors ABC294640 targets mul
Read more →RDHLRedHill Biopharma to Present at the 3rd Annual Autoimmune & Inflammation Leaders' Forum 2015
TEL-AVIV, Israel, March 23, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases,
Read more →RDHLRedHill Biopharma estará presente en el evento online VirtualInvestorConferences.com el 5 de marzo de 2015
TEL-AVIV, Israel, 5 de marzo de 2015 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) ("RedHill" o "la compañía"), una compañía biofarmacéutica de Israel centrada principalmente en los fármacos de administración oral propios y en fase clínica tardía para enfermedades in
Read more →RDHLRedHill Biopharma to Present at VirtualInvestorConferences.com Online Event on
Biopharma to Present at VirtualInvestorConferences.com Online Event on March 5, 2015 TEL-AVIV, Israel, March 3, 2015 RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprie
Read more →RDHLRedHill Biopharma présentera à l
TEL-AVIV, Israël, 4 mars 2015 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ/TASE : RDHL) (« RedHill » ou la « Société »), une société biopharmaceutique israélienne centrée principalement sur les spécialités pharmaceutiques administrés par voie orale à un stade clinique avancé po
Read more →RDHLRedHill Biopharma to Present at Bio-Europe Spring 2015 International Partnering Conference
TEL-AVIV, Israel, March 3, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointe
Read more →RDHLRedHill Biopharma to Present at the 27th Annual ROTH Conference
TEL-AVIV, Israel, March 3, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointe
Read more →RDHLRedHill Biopharma ist Teilnehmer der Online-Veranstaltung von VirtualInvestorConferences.com am 5. März 2015
TEL-AVIV, Israel, 3. März 2015 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) (nachfolgend „RedHill" oder „Unternehmen"), ein israelisches Biopharma-Unternehmen, das sich hauptsächlich firmeneigenen, oral verabreichten Medikamenten für Entzündungs- und gastrointestina
Read more →RDHLRedHill Biopharma to Present at VirtualInvestorConferences.com Online Event on March 5, 2015
TEL-AVIV, Israel, March 3, 2015 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal dis
Read more →RDHLRedHill Biopharma Reports 2014 Fourth Quarter and Year-End Financial Results
Key Highlights Include: Strong cash position of over $34 million, following completion of a $14.4 million U.S. public offering in February 2015 With three ongoing Phase III clinical studies for gastrointestinal diseases, R&D expenses increased to $12.7 million in 2014 compared
Read more →RDHLRedHill Biopharma to Host 2014 Fourth Quarter and Year-End Financial Results Conference Call on February 26, 2015
TEL-AVIV, Israel, Feb. 19, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointe
Read more →RDHLRedHill Biopharma Announces Full Exercise of Underwriters' Over-Allotment Option
TEL-AVIV, Israel, Feb. 18, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointe
Read more →RDHLRedHill Biopharma to Present at the Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference
TEL-AVIV, Israel, Feb. 12, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases,
Read more →RDHLRedHill Biopharma Provides Update on Progress With RHB-104 Ongoing Phase III Program for Crohn's Disease Following FDA Meeting
RedHill and Quest Diagnostics concluded a pre-submission meeting with U.S. FDA regarding RedHill's companion diagnostic test for the detection of MAP bacterium, an extension of RedHill's ongoing RHB-104 Phase III Crohn's disease development program Increasing evidence supports t
Read more →RDHLRedHill Biopharma to Present at the 17th Annual BIO CEO & Investor Conference
TEL-AVIV, Israel, Jan. 28, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases,
Read more →RDHLRedHill Biopharma to Present at Biotech Showcase(TM) 2015 Conference in San Francisco
TEL-AVIV, Israel, Jan. 9, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, i
Read more →RDHLRedHill Biopharma Business Outlook and Anticipated Key Milestones for 2015
Upcoming milestones include: Top-line data from ongoing first Phase III study with RHB-105 for H. pylori infection expected Q2/2015 Top-line data from ongoing Phase III study with BEKINDA (RHB-102) for gastroenteritis and gastritis expected Q3-Q4/2015 TEL-AVIV, Israel, Jan. 5,
Read more →RDHLRedHill Biopharma Announces Acceptance for Review of BEKINDA(TM) European Marketing Application for Oncology Support
The UK MHRA has validated the European marketing application for the indications of chemotherapy and radiotherapy-induced nausea and vomiting; MHRA's feedback is expected during H2/2015 BEKINDA (RHB-102) is a proprietary once-daily oral pill formulation of the antiemetic drug on
Read more →RDHLRedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn's Program
The acquired diagnostic technology is intended for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) bacterium; Increasing evidence supports the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients RedHill is developing a MAP di
Read more →RDHLRedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA(TM)) for Gastroenteritis and Gastritis
The randomized, double-blind, placebo-controlled Phase III study with RHB-102 for acute gastroenteritis and gastritis (the GUARD study) is underway in the U.S., with a planned enrollment of 320 patients Top-line results from the Phase III GUARD study are expected during H2/2015
Read more →RDHLRedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application for Oncology Support
RHB-102, newly branded as BEKINDA , is a proprietary once-daily oral pill formulation of the antiemetic drug ondansetron The European marketing authorization application (MAA) seeks approval of BEKINDA for cancer patients suffering from chemotherapy and radiotherapy-induced naus
Read more →RDHLRedHill Biopharma to Sponsor and Exhibit Its Ongoing Phase III Crohn's Program at the Israeli IBD Society Meeting
TEL-AVIV, Israel, Dec. 2, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today ann
Read more →RDHLRedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT (RHB-103) and initiated its formal review of the application on November 25, 2014 RedHill and IntelGenx continue to work with
Read more →RDHLRedHill Biopharma Reports Results for the Third Quarter of 2014
A strong cash position of approximately $29 million at the end of the third quarter of 2014, enabling the Company to continue to execute its R&D programs including the three ongoing Phase III studies in gastrointestinal indications: RHB-104 for Crohn's disease, RHB-105 for H. pyl
Read more →RDHLRedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014
TEL-AVIV, Israel, Oct. 28, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today an
Read more →RDHLRedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference
TEL-AVIV, Israel, Oct. 22, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal
Read more →RDHLRedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R) (formerly RHB-103)
TEL-AVIV, Israel, Oct. 1, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today ann
Read more →RDHLRedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment
TEL-AVIV, Israel, Sept. 16, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal
Read more →RDHLRedHill Biopharma to Present at the 7th Annual BioPharm America International Partnering Conference
TEL-AVIV, Israel, Sept. 15, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal
Read more →RDHLRedHill Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
TEL-AVIV, Israel, Sept. 4, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal
Read more →RDHLRedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis
The randomized, double-blind, placebo-controlled, parallel group Phase III study with RHB-102 (the GUARD study) will enroll 320 acute gastroenteritis patients in the U.S. Acute gastroenteritis is an inflammation of the gastrointestinal tract causing nausea and vomiting, with a p
Read more →RDHLRedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA
In order to enhance statistical powering and expedite recruitment, RedHill has increased the number of subjects and clinical sites, respectively, in the ongoing RHB-105 Phase III ERADICATE Hp study, with top-line data currently expected in the first half of 2015 FDA has permitte
Read more →RDHLRedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101
Potentially expanding its gastrointestinal-focused pipeline, RedHill has secured an option to acquire RP101 from Dresden-based RESprotect GmbH, a spin-off from the Fraunhofer-Society RP101 has completed several Phase I and Phase II clinical studies RP101 has been granted Orphan
Read more →RDHLRedHill Biopharma Reports Results for the Second Quarter of 2014
A strong cash position of approximately $34 million at the end of the second quarter of 2014, following the acquisition of rights to MESUPRON , a Phase II drug targeting gastrointestinal cancers Top-line data from the Phase III study of RHB-105 for H. pylori infection expected i
Read more →RDHLRedHill Biopharma to Host Second Quarter 2014 Financial Results Conference Call on July 24, 2014
TEL-AVIV, Israel, July 16, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including cancer, today ann
Read more →RDHLRedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG
RedHill expands its late clinical-stage gastrointestinal-focused pipeline with MESUPRON , an oncology drug targeting gastrointestinal and other solid tumor cancers licensed from Wilex AG MESUPRON completed several Phase I and Phase II clinical studies, including a Phase II proof
Read more →RDHLRedHill Biopharma Announces Positive Preliminary Pre-Clinical Data With RHB-104 for the Treatment of Type 1 Diabetes
The Company, primarily focused on gastrointestinal and inflammatory-related diseases and conditions, including cancer, is currently assessing the possibility of a Phase II proof of concept study for type 1 diabetes, subject to final results and an independent report expected in t
Read more →RDHLRedHill Biopharma to Present at the 2014 BIO International Convention
TEL-AVIV, Israel, June 18, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs for the t
Read more →RDHLRedHill Biopharma to Present at the Wells Fargo Securities 9th Annual Healthcare Conference
TEL-AVIV, Israel, June 11, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs for the t
Read more →RDHLRedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn's Program
The Japan Patent Office (JPO) has issued a Decision to Grant a Patent covering RHB-104 with a 2029 expiry date RedHill has initiated a long-term population pharmacokinetic study with RHB-104 for Crohn's disease, designed to satisfy regulatory requirements for future potential ma
Read more →RDHLRedHill Biopharma to Present at Jefferies 2014 Global Healthcare Conference
TEL-AVIV, Israel, June 2, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs for the tr
Read more →RDHLRedHill Biopharma Announces FDA Clearance for Phase III Study With RHB-102 Planned to Commence in Q3/2014
FDA's clearance of RedHill's Investigational New Drug ("IND") amendment allows the initiation of a Phase III clinical study for a new undisclosed indication with RHB-1021, a proprietary, once-daily, extended release oral pill formulation of the antiemetic drug ondansetron In par
Read more →RDHLRedHill Biopharma and IntelGenx Report Positive RHB-103 Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014
TEL-AVIV, Israel, May 21, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today reported, together w
Read more →RDHLRedHill Biopharma to Present at the ChinaBio Partnering Forum 2014
TEL-AVIV, Israel, May 1, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs for the treatment of inflamm
Read more →RDHLRedHill Biopharma Reports Results for the First Quarter of 2014
Key financial highlights include: A first profitable quarter, with net income of $3.4 million, primarily attributed to the $7 million upfront payment received from Salix Pharmaceuticals as part of the licensing transaction for the rights to RedHill's RHB-106 encapsulated bowel p
Read more →RDHLRedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014
RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers In light of the positive results, and subject to regulatory requirements, the Company plans to submit, during the third quarter of this year, a European marke
Read more →RDHLRedHill Biopharma to Host First Quarter 2014 Financial Results Conference Call on May 1, 2014
TEL-AVIV, Israel, April 29, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the
Read more →RDHLRedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study With RHB-103 (Migraine) to Support European Marketing Application Planned for Q3/2014
TEL-AVIV, Israel, April 28, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, together with IntelGenx
Read more →RDHLRedHill Biopharma and IntelGenx Provide an Update on FDA's Ongoing Review of the NDA for RHB-103 Oral Migraine Film
TEL-AVIV, Israel, April 24, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, together with IntelGenx
Read more →RDHLRedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application
The Company concluded a positive scientific advice meeting with the UK MHRA regarding RHB-102 and plans to submit, during the second half of the year, a European marketing application for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patien
Read more →RDHLRedHill Biopharma to Present at the 26th Annual ROTH Conference
TEL-AVIV, Israel, March 7, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the
Read more →RDHLRedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property
RHB-102 is a proprietary once-daily oral antiemetic RedHill has secured from Temple University direct rights to the original RHB-102 patents and has terminated its agreement with SCOLR Pharma Inc. Following a pre-NDA meeting on RHB 102's development for oncology support, RedHil
Read more →RDHLRedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
TEL-AVIV, Israel, March 3, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelG
Read more →RDHLRedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
TEL-AVIV, Israel, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHi
Read more →RDHLRedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results
2013 Key Highlights Include: Strong cash position of over $34 million, as of February 2014, following two private placements in early 2014 and the exercise of warrants, including by directors and management Net R&D expenses of $8.1 million during 2013, compared to $6.5 million
Read more →RDHLRedHill Biopharma and IntelGenx Receive Complete Response Letter From FDA for RHB-103 Oral Film for Acute Migraines
FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; RedHill and IntelGenx plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks, based on avai
Read more →RDHLRedHill Biopharma Closes Previously Announced $11.7 Million Private Placement
TEL-AVIV, Israel, Jan. 22, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations a
Read more →RDHLRedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement
TEL-AVIV, Israel, Jan. 14, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations a
Read more →RDHLRedHill Biopharma Provides Update on PK Program in Support of Ongoing RHB-104 Phase III Crohn's Study
Preliminary positive safety results received from a Phase I study with RHB-104 in 84 healthy adult subjects Additional PK studies with RHB-104 are planned, including long-term population PK and drug-drug interaction studies, to support potential future marketing applications TE
Read more →RDHLRedHill Biopharma Announces Definitive Agreement for $2.5 Million Private Placement From Broadfin Capital LLC
TEL-AVIV, Israel, Dec. 31, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations a
Read more →RDHLRedHill Biopharma Reports Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Study
The positive results from the pharmacokinetic study support the continuation of the ERADICATE Hp study - a Phase III clinical study currently underway in the U.S., evaluating RHB-105 as a first-line therapy for H. pylori bacterial infection The objectives of the PK study were to
Read more →RDHLRedHill Biopharma Announces First Patients Dosed in Phase III Study of RHB-105 for H. pylori Infection
The first patients have been dosed in the ERADICATE Hp study - a randomized, double-blind, placebo-controlled, Phase III study evaluating RHB-105 as a first-line therapy for H. pylori bacterial infection Seven of the eight clinical sites in the U.S. are actively enrolling patien
Read more →RDHLRedHill Biopharma Announces First Patient Dosed in Phase III Study of RHB-104 for Crohn's Disease
First patient has been recruited and dosed in the MAP US study - a randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the safety and efficacy of RHB-104 for treatment of Crohn's disease The Phase III study is expected to enroll 240 subjects in over
Read more →RDHLRedHill Biopharma Announces Positive Scientific Advice Meeting and European Marketing Application Strategy for RHB-103 (Migraine)
The Company and its co-development partner, IntelGenx Corp., held a Scientific Advice meeting with the German pharmaceuticals regulation authority (BfArM) and plan to submit a Marketing Authorization Application (MAA) to market RHB-103 in Europe during the first half of 2014 RHB
Read more →RDHLRedHill Biopharma Reports Results for the Third Quarter of 2013
Key highlights include: Commencement of the MAP US study - a Phase III clinical study in North America and Israel with RHB-104 for the treatment of Crohn's disease Commencement of the ERADICATE Hp study - a Phase III clinical study in the U.S. with RHB-105 for the treatment of
Read more →RDHLRedHill Biopharma to Present at the 19th Annual Bio-Europe International Partnering Conference
TEL-AVIV, Israel, Oct. 31, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations a
Read more →RDHLRedHill Biopharma Initiates Phase III Study of RHB-105 for H. pylori Infection
RedHill has initiated the patient screening process in the ERADICATE Hp study - a randomized, double-blind, placebo-controlled Phase III study to evaluate the safety and efficacy of RHB-105 as a first-line therapy for H. pylori bacterial infection Subjects will be treated with R
Read more →RDHLRedHill Biopharma to Present at the 2013 Annual BioNetwork Conference
TEL-AVIV, Israel, Oct. 23, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations a
Read more →RDHLRedHill Biopharma Announces FDA Acceptance of IND Application for RHB-105 (H. pylori) Phase III Study - to Commence Shortly
The Phase III study is expected to commence in the U.S. by the end of this month RHB-105 is a new and proprietary combination therapy in an oral capsule for the treatment of H. pylori bacterial infection RedHill recently commenced another Phase III study in the U.S. with RHB-1
Read more →RDHLRedHill Biopharma's RHB-104 Combination Achieves 80% Remission in Independent Pediatric Crohn's Study
The retrospective study, presented at the 2013 American College of Gastroenterology (ACG) Annual Scientific Meeting, demonstrated strong results with a high remission rate of 80% RedHill's RHB-104 is a new and improved proprietary single-pill formulation of the combination of ac
Read more →RDHLRedHill Biopharma Reports Positive PK Clinical Studies Towards Planned NDA with RHB-102 (Anti-Emetic)
Following the positive results from two supportive pharmacokinetic (PK) studies, the Company plans to file a new drug application (NDA) in the first quarter of 2014 and is seeking a pre-NDA meeting with the FDA RHB-102 is a proprietary, extended release, once-daily oral formulat
Read more →RDHLRedHill Biopharma Initiates Phase III Study of RHB-104 for Crohn's Disease
RedHill has initiated the patient screening process in a randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the safety and efficacy of RHB-104 for treatment of Crohn's disease (the MAP US study) The Phase III study is expected to enroll 240 subject
Read more →RDHLRedHill Biopharma to Present at the Annual BioPharm America International Partnering Conference
TEL-AVIV, Israel, Sept. 11, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations
Read more →RDHLRedHill Biopharma Announces Positive Pre-Clinical Results for Lupus With RHB-104
The Company is assessing the possibility of a Phase IIa proof of concept study in systemic lupus erythematosus as a next step RedHill expects to commence a Phase III study with RHB-104 for Crohn's disease in the U.S. during the third quarter of 2013 (the MAP US study), and plans
Read more →RDHLRedHill Biopharma to Present at the Stifel Nicolaus Annual Healthcare Conference
TEL-AVIV, Israel, Sept. 3, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations a
Read more →RDHLRedHill Biopharma Announces Positive European Regulatory Meetings Regarding Its European Phase III Plan for RHB-104 (Crohn's)
The Company recently held successful Scientific Advice Meetings with the UK and Swedish pharmaceutical regulatory agencies to discuss its European Phase III strategy with RHB-104 for Crohn's disease The European trial will be the second Phase III study with RHB-104 and is expect
Read more →RDHLRedHill Biopharma Announces Positive Pre-Clinical Rheumatoid Arthritis Results With RHB-104 and Plans for a Phase IIa Study
The planned phase IIa, proof of concept, clinical study will assess the efficacy and safety of RHB-104 in patients suffering from rheumatoid arthritis (RA) RA is one of the most common inflammatory diseases, with 2012 worldwide sales of therapies exceeding $20 billion A Phase I
Read more →RDHLRedHill Biopharma Reports Results for the Second Quarter of 2013
RedHill continues advanced preparations for the Phase III study with RHB-104 (Crohn's) and Phase II/III study with RHB-105 (H. pylori) Key Highlights include: FDA acceptance of RHB-103 (migraine) NDA for substantive review, with a PDUFA goal date of February 3, 2014 Commenceme
Read more →RDHLRedHill Biopharma Provides Update on Planned NDA Filing for RHB-102 (Once Daily Anti-Emetic) in Q1 2014 and Commences PK Program
Following a Type B meeting with the FDA in February 2013, the Company commenced the first of two supplementary pharmacokinetic studies with RHB-102, with a second comparative bioavailability study planned to commence next month The Company expects to receive results from both st
Read more →RDHLRedHill Biopharma to Present at the JMP Securities Annual Healthcare Conference in New York
TEL-AVIV, Israel, July 3, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, patent-protected, new formu
Read more →RDHLREDHILL BIOPHARMA LTD. 21 Ha'arba'a Street Tel-Aviv 64739 Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on
REDHILL BIOPHARMA LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on July 31, 2013 Annual General Meeting of Shareholders of Redhill Biopharma Ltd (the "Company"), will be held at the offices of the Company, 21 Ha'arba'a Street, Tel-Aviv, Israel on July 31, 2
Read more →RDHLConvenience Translation from Hebrew REDHILL BIOPHARMA LTD. (the Company ) Notice is hereby given that the annual meeting of shareholders of the Company will be held on Wednesday
Convenience Translation from Hebrew REDHILL BIOPHARMA LTD. Notice is hereby given that the annual meeting of shareholders of the Company will be held on Wednesday, July 31, 2013 at 11:00 a.m. Israel time (the "Meeting"), at the Company's offices, located at, 21 Ha'arba'a Stre
Read more →RDHLRedHill Biopharma Announces FDA Acceptance for Review of RHB-103 NDA for Acute Migraine and PDUFA Goal Date of February 3, 2014
The RHB-103 New Drug Application (NDA) for marketing approval in the U.S. is subject to a standard 10-month review period and will have a Prescription Drug User Fee Act (PDUFA) action date (targeted date for completion of FDA review) of February 3, 2014 The Company recently rece
Read more →RDHLRedHill Biopharma Commences Patient Screening in a Phase IIa Clinical Trial With RHB-104 for Multiple Sclerosis
The open label Phase IIa study is designed to assess the efficacy and safety of RHB-104 in Multiple Sclerosis (MS) patients. The study follows successful completion of 4 pre-clinical studies A first Phase III clinical trial with RHB-104 for Crohn's disease (the "MAP US Study") i
Read more →RDHLRedHill Biopharma Announces Positive FDA Meeting Regarding the Regulatory Path Towards NDA Submission of RHB-101 for the Treatment of Congestive Heart Failure and Hypertension
Following the prior successful completion of four pharmacokinetic (PK) clinical studies, the Company held a Type B meeting regarding RHB-101 with the U.S. Food and Drug Administration (FDA) Based on the FDA's positive feedback, the Company plans to conduct additional Chemistry,
Read more →RDHLRedHill Biopharma to Present at the Jefferies 2013 Global Healthcare Conference in New York
TEL-AVIV, Israel, May 28, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, patent-protected, new formu
Read more →RDHLRedHill Biopharma Reports Financial Results for the First Quarter of 2013
The Company Maintains a Strong Balance Sheet Following Submission to the FDA of Its First New Drug Application (NDA) for RHB-103 (Migraine) RedHill Plans to Submit a Second NDA, for RHB-102 (Oncology Support Anti Emetic), by the First or Second Quarter of 2014 and Continues to A
Read more →RDHLRedHill Biopharma Submits New Drug Application to U.S. FDA for RHB-103 Anti-Migraine Oral Thin Film
TEL-AVIV, Israel, March 27, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, patent-protected, new for
Read more →RDHLRedHill Biopharma Receives Positive Feedback From a Scientific Advice Meeting in Europe Regarding RHB-101 (Hypertension) Marketing Application Plan
The Company held a Scientific Advice meeting regarding RHB-101 with the Danish Health and Medicines Authority (DKMA) Following the positive results of the meeting, the Company intends to submit a Marketing Authorization Application (MAA) to market RHB-101 in Europe, with Denmark
Read more →RDHLRedHill Biopharma to Present at the 25th Annual ROTH Conference
TEL-AVIV, Israel, March 6, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, patent-protected, new form
Read more →RDHLRedHill Biopharma Provides Update on Development Progress and Planned NDA Submission for RHB-102 (Oncology Support Anti-Emetic)
Following a successful comparative bioavailability trial, the Company met with the FDA to discuss its planned New Drug Application (NDA) filing for RHB-102 Company plans to file the RHB-102 NDA in Q4/2013 RHB-102 is a proprietary, extended release, once-daily oral formulation o
Read more →RDHLRedHill Biopharma Reports 2012 Fourth Quarter and Year-End Results
Key Planned Milestones for 2013 Include Commencement of Phase III and Phase II/III Studies With RHB-104 (Crohn's Disease) and RHB-105 (H. pylori), Respectively, and New Drug Application (NDA) Filings With RHB-102 (Oncology Support Antiemetic) and RHB-103 (Acute Migraine) TEL-AVI
Read more →RDHLRedHill Biopharma Announces Notice of Allowance From the United States Patent and Trademark Office for Its Cardio Drug RHB-101
RHB-101 is a proprietary, controlled release, once-daily formulation of carvedilol for the treatment of hypertension, congestive heart failure and left ventricular dysfunction The expected expiration date of the US patent is 2024 TEL-AVIV, Israel, Feb. 19, 2013 (GLOBE NEWSWIRE)
Read more →RDHLRedHill Biopharma Announces Date of 2012 Financial Results and Corporate Update Conference Call
TEL-AVIV, Israel, Feb. 14, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL), an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage, patent-protected, new formulations and combinations of existing dru
Read more →RDHLPress Release Date
Date: February 14, 2013 RedHill Biopharma Announces Date of Financial Results and Corporate Update RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL), an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage, patent-protect
Read more →RDHLRedHill Biopharma Announces Issuance of New U.S. Patent and Provides Update on RHB-104 for Treatment of Crohn's Disease
Patient Recruitment in an Initial Phase III Study is Planned to Commence Q2/2013; Multi-Site Initiation Process is Underway; Newly Issued Patent Expires no Earlier Than 2029 Additional Planned and Required Studies, Which Include a Second Phase III Crohn's Disease Trial in Europe
Read more →RDHLRedHill Biopharma Announces NASDAQ Listing and Commencement of Trading Under the Ticker "RDHL"
Trading on NASDAQ to Commence Today, Thursday, December 27th, 2012 Following Final Approvals From SEC and NASDAQ The Listing Does Not Include Capital Raising as Part of the Registration Process RedHill Biopharma Recently Completed a Private Placement of Approximately $6.5 Milli
Read more →Competitive Position
How RDHL ranks across every disease it competes inCompetitive Position is a premium feature
See how RDHL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial